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Cardiac allograft arteriosclerosis (CAA) is the leading cause of death in cardiac transplantation 
recipients. Nitric oxide (NO) produced by NO donors or nitric oxide synthase (NOS) inhibits 
smooth muscle cell proliferation and migration, promotes endothelial cell proliferation, blocks 
endothelial cell apoptosis, prevents platelet and leukocyte adhesion and platelet aggregation. NO 
has been shown to inhibit intimal hyperplasia and suppress the development of cardiac allograft 
arteriosclerosis. Conversely, induction of NO in cardiomyocytes leads to myocardial apoptosis 
and suppresses cardiac function, mainly represented by decreased cardiac contractility. Based on 
these studies, we hypothesize that cell type-specific overexpression of eNOS or iNOS, in smooth 
muscle or endothelial cells, will inhibit the development of cardiac allograft arteriosclerosis 
without suppressing cardiac function. To test this hypothesis, we developed two gene delivery 
systems that specifically express NO in smooth muscle or endothelial cells. One system we 
constructed is adenoviral vectors that employed the fms-like tyrosine kinase-1 (Flt-1, -748 ~ 
+284 bp), or the intercellular molecule 2 (ICAM2, -292 ~ +44 bp) promoters to drive the human 
iNOS specific expression in endothelial cells. Another system we developed is vascular-specific 
iNOS inducible transgenic mice that employed the GeneSwitch system (Invitrogen) and vascular 
–specific promoter. We obtained two iNOS transgenic lines, in which iNOS can be induced by 
the ligand mifepristone with the supply of the Switch protein. To determine the efficacy of eNOS 
endothelial-specific expression on suppression of cardiac allograft arteriosclerosis, we employed 
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iNOS) in smooth muscle or endothelial cells 
Jing Lei, PhD 
University of Pittsburgh, 2008
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eNOS transgenic mice in which the human eNOS promoter was driving the human eNOS 
expression. In a mouse heterotopic transplantation model, the male transgenic and female wild-
type counterparts were used as donor and recipient, respectively. The donor grafts were 
harvested 60 days after transplantation and the percentage of vessel occlusion was determined. 
The vessel occlusion developed in the transegenic donor did not show significant difference 
compared to the wild-type control. As an alternative approach, the eNOS/GTPCH double 
transgenic mice will be used as donor and its efficacy will be determined. We hope that these 
proof-of -principle studies will serve as the basis for the development of an effective treatment 
strategy to prevent cardiac allograft arteriosclerosis. 
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1.0  INTRODUCTION 
Cardiac transplantation has become an effective treatment for the end-stage cardiac diseases. 
Current immunosuppressive regimens control acute rejection and has achieved greater than 90% 
of one year survival (1). However, cardiac allograft arteriosclerosis constitutes the major 
limitation to long-term survival of the recipients. This disease can be detected by coronary 
angiography in 6-18% of cardiac recipients at 1 year and in 50% of recipients at 5 years (2, 3). 
The development of cardiac allograft arteriosclerosis has become the principle cause of late 
death and allograft dysfunction (4-6). At present, effective treatments for this disease have not 
yet been found. Retransplantation remains the only alternative, but this is not an effective option 
given the shortage of organs and only 48% of patients are alive 1-year after retransplantation (7). 
In addition, cardiac allograft arteriosclerosis can still develop in the second allograft. 
1.1 CHARACTERISTICS AND PROPOSED MECHANISM OF CARDIAC 
ALLOGRAFT ARTERIOSCLEROSIS  
Cardiac allograft arteriosclerosis is characterized by a diffuse, concentric form of arteriosclerosis 
that affects both small intramyocardial and large coronary arteries and veins (8). It is hallmarked 
by intimal thickening resulting from smooth muscle cell proliferation and migration from the 
tunica media to the intimal layer and by a paucity of collateral neovascularization (9). This 
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process appears along the entire length of the affected vessels. This process is not unique to 
cardiac allograft coronary vessels, but is seen in all solid organ allograft vascular beds (190). The 
intimal elastic lamina is usually inact, with occasional deposition of calcium (191). 
The mechanism for cardiac allograft arteriosclerosis is still not clear. It is proposed that 
both immunological factors and non-immunological factors contribute to cardiac allograft 
arteriosclerosis. The immunological factors include histocompatibility (199, 200, 201), acute 
rejection (202-205) and chronic inflammation. Non-immunological factors are related to 
ischemia/referfusion injury (206), cytomeganovirus infection (207, 208), age (205, 209), sex 
(209), hypertension (209), hyperlipidemia (210, 211), heperhomocysteinemia (212-215), insulin 
restistance (216), obesity and smoking (192). The endothelium functions to regulate vascular 
tone, prevent coagulation and inhibit thrombosis. Endothelial injury likely initiates the 
development of cardiac allograft arteriosclerosis. During transplantation, the first injury to the 
donor allograft is perfusion and ischemia, which injures and activates endothelial cells to express 
major histocompatibility complex (MHC) class I and II antigens (196, 217, 218). These antigens 
activate recipient T cells to secrect cytokines, including interlekin-2 (IL-2), IL-4, IL-5, IL-6, 
interferon-γ (INF-γ), tumor necrosis factor-α (TNF-α) and TNF-β (218). These cytokines 
promote proliferation of alloreactive T cells and stimulate donor endothelial cells to upregulate 
adhesion molecules, including vascular cell adhesion molecule-1 (VCAM-1) and intercellular 
adhesion molecule-1 (ICAM-1) (195, 218). The upregulated adhesion molecules recruit 
leukocytes, platelets and macrophages which adhere to endothelium and initiate a localized and 
sustained inflammatory response. Some inflammatory cells transmigrate across the endothelial 
barrier into the intima. The inflammatory response activates endothelial cells to express 
endothelin-1, a vessel constrictor that perpetuates the development of cardiac allograft 
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arterioslerosis (219, 220). The inflammatory response stimulates smooth muscle cells to secret 
C-reactive protein-1 (CRP-1) (221), which downregulates eNOS expression in endothelial cells 
(222) and upregulates angiotensin-1 receptor in smooth muscle cells (223). The inflammatory 
response also stimulates caridomyocytes and the vascular wall to release vascular endothelial 
growth factor (VEGF) (14), aFGF (12), PDGF-AA (11, 12), thrombospondin-1 (197) and matrix 
metalloproteinase family: MMP2, MMP3, MMP9 and MMP13 (224-226). Other growth factors 
and cytokines that are upregulated include PDGF-BB (11, 227), bFGF (11), TNF-α (10, 11, 13), 
HB-EGF (13) and TGF-β (228). Some of the growth factors and cytokines, including PDGF-AA, 
PDGF-BB, TGF-β, TNF-α, EGF, FGF, bFGF and IGF-1, thrombosponding-1 and CRP, initiate 
the transformation of vascular smooth muscle cells from the normal non-proliferative contractile 
phenotype to a proliferative and synthetic phenotype (15), leading to the proliferation and 
migration of smooth muscle cells from tunica media to intima layer (10, 16, 17) as well as matrix 
deposition (18-20). The upregulated matrix metalloproteinases promote the degradation of 
matrix proteins and faciliates smooth muscle cell migration (229).  
The development of cardiac allograft arteriosclerosis is not only associated with a cellular 
immune response, but also is the result of humoral rejection. The majority of patients produce 
anti-human leukocyte antigen antibodies (anti-HLA) after transplantation (230-233). The 
production of anti-HLA antibodies is significantly associated with graft survivral rate and the 
severity of graft vasculopathy (234, 235). 
The extent of cardiac allograft arteriosclerosis is determined by the balance of two inter-
related processes: positive and negative remodeling of coronary vessels. Positive remodeling 
leads to vessel lumen enlargement while negative remodeling means the process of intimal 
hyperplasia. Some studies (193, 194) showed even though intimal hyperplasia develops at 1 to 3 
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years after transplantation, positive remodeling offsets the negative remodeling. In these cases, 
vessel lumen enlarges to a greater extent than the intimal hyperplasia area. However, over time 
after transplantation, negative remodeling typically dominates and coronary vessel lumen 
exhibits shrinkage. Gradually, cardiac allograft arteriosclerosis develops. 
.  
1.2 BIOLOGICAL CHARACTERISTICS OF NO  
Nitric Oxide (NO) is an intra- and intercellular signaling molecule that plays important roles in 
many physiological and pathological processes, including vasodilatation, neuronal transmission, 
immunomodulation, and cardiac contraction (21-26). In 1992, NO was named as “molecule of 
the year” by Science. In 1998, Nobel Prize in Physiology and Medicine was awarded to Drs 
Robert F. Furchgott, Louis J. Ignarro and Ferid Murad for their discoveries of NO as a signaling 
molecule in the cardiovascular system. Over the last two decades, NO has been studied 
extensively.  
NO has a half life of about 6 seconds in biological systems. NO is highly diffusible and 
can reach adjacent cells quickly. NO can be converted from NO donor, e.g. S-nitroso-N-
acetylpenicillamine (SNAP), or synthesized from substrate L-arginine under the catalysis of 
nitric oxide synthase (NOS). There are three NOS isoforms: endothelial NOS (eNOS), neuronal 
NOS (nNOS) and inducible NOS (iNOS). eNOS is mainly expressed in endothelial cells and is 
also found in smooth muscle cells, cardiomyocytes, bone cells and neurons. nNOS is mainly 
expressed in neurons and is also found in skeletal muscle, the pancreas and the kidneys. In 
contrast, iNOS is not expressed under normal condition but can be induced in almost every cell 
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type by a variety of stimuli such as inflammatory cytokines, microbes, microbial products (LPS) 
and mechanical perturbation (27-30).  
eNOS and nNOS are constitutively expressed and the activity of these isoforms is 
activated by increasing intracellular Ca2+ fluxes that results in calmodulin binding to the enzyme. 
In contrast, iNOS activity is not dependent on Ca2+ fluxes. eNOS and nNOS generates NO in 
nanomolar level (25, 31, 32), while iNOS generates NO in micromolar concentration range for 
long periods of time (22, 23, 25).   
1.3 VASOPROTECTIVE ROLES OF NO  
NO has been shown to exert many vasoprotective roles in vascular system, including inhibition 
of smooth muscle cell proliferation and migration, enhancement of endothelial cell proliferation 
and migration, inhibition of endothelial cell apoptosis, suppression of platelet aggregation and 
inhibition of platelet, leukocyte and monocyte adhesion to endothelium. These protective roles 
will be described in detail in the following section. 
1.3.1 No inhibits SMC proliferation and migration 
The inhibitory effect of NO on SMC proliferation was first demonstrated in 1989 by Garg et al. 
(33). Three NO donors, SNAP, sodium nitroprusside (SNP), and isosorbide dinitrate (ISDN), 
inhibited SMC proliferation in a dose-dependent pattern. SMC proliferation was assayed by 
serum-induced [3H] thymidine incorporation. This inhibitory effect was also exhibited by 8-
bromo-cGMP. However, SNAP-induced inhibition of proliferation was prevented when 
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hemoglobin, which scavenges NO, was present. In contrast, SNAP-induced antiproliferation was 
accelerated when superoxide dismutase (SOD) was added. SOD catalyzes the degradation of 
superoxide, while superoxide oxidizes NO to form peroxynitrite ONOO·-.  
Cornwell et al. (34) further showed that the cytokine IL-1β or the NO donor, SNAP or 
SNP, inhibited PDGF-induced SMC proliferation. NO increased cyclic GMP (cGMP) levels, 
which activated cAMP kinase. However, NO did not change cAMP levels. The cyclic AMP 
kinase inhibitor (R) p-bromoadenosine 3’, 5’-cyclic monophosphorothioate (Rp-8-BrcAMP[S]) 
reversed NO induced inhibition of SMC proliferation. However, the cyclic GMP kinase inhibitor 
[(R) p-bromoguanosine 3’, 5’-cyclic monophosphorothioate (Rp-8-BrcGMP[S]) did not exhibit 
this inhibitory effect. Garg and Cornwell’s results demonstrated that NO inhibits SMC 
proliferation through cGMP and cAMP kinase dependent pathways, but not cAMP and cGMP 
kinase dependent pathway. In 1995, Guo et al. also confirmed that SMC proliferation was 
inhibited by an NO donor 4-hydroxymethyl-furazan-3-carboxylic acid-2-oxide (CAS 1609), but 
not by the non-NO donating control compound 4-hydroxymethyl-furazan-3-carboxylic acid 
(C93-4845) (35). 
 
NO has also been shown to inhibit SMC migration (36, 37). In 1995, Dubey et al. 
reported the antimigratory effect of NO on SMC cells (36). SMC migration was induced by 
angiotensin II in a dose-dependent pattern, which was evaluated using a modified Boydens 
Chamber. Angiotensin II induced SMC migration was suppressed by the NO donor SNAP or 
SNP, or 8-bromo cGMP in a dose-dependent pattern. This suppression was reversed by 
hemoglobin and exaggerated by SOD. The antimigratory effect exhibited by SNAP was partially 
reversed by the cGMP-dependent protein kinase inhibitor, KT5832, or the inhibitor of soluble 
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guanylate cyclase LY 83583. However, this antimigratory effect was not changed in the presence 
of the adenylate cyclase inhibitor, DDA, or the cAMP-dependent protein kinase inhibitor Rp-
cAMP. This antimigratory effect was also exhibited when L-arginine was present in SMC in 
which iNOS was induced by IL-1β. In contrast, the presence of D-arginine did not show any 
antimigratory effect. Moreover, the NOS inhibitor L-NAME completely abrogated this 
antimigratory effect. These data suggest that NO inhibits SMC migration partially through a 
cGMP-dependent pathway. This inhibitory effect of NO was also confirmed by Sarkar et al. in 
1996 when three other NO donors, diethylamine NONOate, S-nitrosoglutathione and Spermine 
NONOate, suppressed SMC migration (37). 
These studies demonstrate that NO inhibits SMC proliferation and migration partially 
through the cGMP-dependent pathway. 
1.3.2 NO enhances proliferation and migration of endothelial cells and inhibits apoptosis   
In 1994, Ziche et al. reported that NO promoted endothelial cell proliferation and migration (95). 
Three NO donors, SNP, ISDN and glyceryl trinitrate, enhanced proliferation of coronary venular 
endothelial cells, which was determined by [3H]-thymidine incorporation and couting cell 
number. These NO donors also increased the migration of endothelial cells. In contrast, these 
promoting effects were reversed by the NOS inhibitor L-NMMA, L-NNA or L-NAME. In 1995, 
Guo et al. also showed that NO promoted endothelial cell proliferation in both cultured 
endothelial cells and injured carotid arteries (35). NO donor 4-hydroxymethyl-furazan-3-
carboxylic acid-2-oxide (CAS-1609) increased proliferation of rat aortic endothelial cells, which 
was determined by counting the cell number and incorporating 5-bromo-2’-deoxy-uridine 
(BrdU) into DNA. However, this increase was not observed when cells were treated by a non-
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NO-donating control compound, 4-hydroxymethyl-furazan-3-carboxylic acid (C93-4845). 
Moreover, endothelial regeneration was accelerated in a rat carotid artery injury model when 
treated by the NO donor CAS-1609, but not by its control compound C93-4845 without the NO 
moiety. 
In 1997, Tzeng et al. demonstrated that NO attenuated LPS-induced endothelial cell 
apoptosis (96). Infection by adenoviral vector AdCMV-iNOS in sheep arterial endothelial cells 
resulted in a significant enhancement of endothelial cell proliferation without cytotoxicity when 
assayed by 51Chromium release compared to the AdCMV-lacZ control. Moreover, AdCMV-
iNOS infection did not induce endothelial cell apoptosis. In contrast, it inhibited LPS-induced 
apoptosis, which was detected by internucleosomal DNA fragmentation. These data demonstrate 
that NO enhances endothelial cell proliferation and migration and inhibits apoptosis. 
1.3.3 No suppresses platelet aggregation 
In 1983, Mellion et al. demonstrated that NO suppressed human platelet aggregation (38). When 
human platelets were induced to aggregate by aggregating agents, including ADP, collagen, 
U46619, or sodium arachidonate, three NO donors, SNAP, S-nitrosocysteine, or S-nitroso-β–D-
thioglucose inhibited platelet aggregation in a dose-dependent fashion. In contrast, this 
antiaggregatory effect was attenuated when methemoglobin, a hemoprotein with a high affinity 
for NO, was present. Concomitantly, the three NO donors also induced a rapid and marked 
increase in the cGMP levels. This increase was partially reversed by hemoproteins. Meanwhile, 
cAMP levels were not changed. Moreover, guanylate cyclase that was purified from platelets, 
was significantly activated by the three NO donors while this activation was attenuated by 
hemoproteins. This antiaggregatory effect of NO was also confirmed by McCall et al. (39). 
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1.3.4 NO inhibits platelet, leukocyte and monocyte adhesion to endothelium 
In 1987, Radomski et al. demonstrated that NO supppressed human platelet adhesion to the 
vascular endothelium (40).  Human platelets were radiolabelled with indium-111-oxine and 
added onto cultured bovine aortic endothelial cell monolayers. Exogenous NO, or bradykinin, 
which induced NO production and prostacyclin, significantly inhibited platelet adhesion. 
Addition of aspirin to bradykinin-treated cells, which completely abrogated prostacyclin 
synthesis, did not affect the adhesion of platelets to the endothelium. In contrast, addition of 
haemoglobin into bradykinin-treated cells, significantly increased the adhesion.  On the contrary, 
this enhancement of adhesion was not observed when the cells were pretreated with 
methaemoglobin, which does not scavenge NO. These results clearly indicate that suppression of 
platelet adhesion is NO-dependent. In 1996, Yan et al. further confirmed the inhibitory effect of 
NO (41) in a rat carotic artery injury model. Platelets were prelabelled with 111In-oxine and 
injected intraveneously. This was followed by injection of the NOS inhibitor L-NAME. iNOS 
was strongly induced in the neointima and media layer of the injured segment, but not in the 
control intact segment. L-NAME significantly increased the deposition of platelets on the injured 
segment, but not on the control segment. This deposition was L-NAME dose-dependent and was 
not observed when using its inactive enantiomer, D-NAME. L-NAME treatment also 
significantly decreased blood flow by 32%, which indicates that NO plays an important role on 
regulating local blood flow. 
In 1991, Kubes et al. reported that NO inhibits leukocyte adhesion to vascular 
endothelium (42). Inhibition of endogenous NO production in postcapillary venules by L-
NMMA or L-NAME, increased leukocyte adhesion to the endothelium by 15 times and reduced 
wall shear rate by half compared to the control. Leukocytes adhesion was observed in single 
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venules by intravital video microscopy. Leukocyte adhesion was completely reversed by L-
arginine and by a leukocyte adhesion glycoprotein CD18-specific antibody IB4, while D-arginine 
had no effect. Moreover, SOD, which prevents NO inactivation, has been reported to reverse the 
adhesion of leukocytes to mesenteric venules (43). To further elucidate the role of NO on 
leukocytes adhesion, Hickey et al. compared adhesion of leukocytes to endothelium between 
iNOS-deficient and wild-type mice (44). Between 2 and 4 hours after LPS administration, the 
speed of leukocyte rolling and the number of adherent leukocytes in cremasteric postcapillary 
venules of the iNOS-deficient mice was significantly higher than that of wild-type mice. The 
number of leukocytes adherent to postsinusoidal venules in liver was also significantly elevated 
in iNOS-deficient mice relative to the wild-type mice. Moreover, the number of leukocytes 
interacting with E-selectin in iNOS-deficient mice was significantly higher than that of the wild-
type mice.   
In 1998, Peng et al. demonstrate that NO inhibited monocyte-endothelial cell interaction 
(45). When human saphenous vein endothelial cells were treated with the NOS inhibitor LNMA, 
eNOS activity was inhibited by greater than 85% and this resulted in a significant increase in 
monocyte adhesion to endothelial cells. When endothelial cells were co-cultured with 
RAW264.7 cells stimulated by LPS and IFN-γ, NO generated from the RAW264.7 cells 
significantly prevented monocyte adhesion to the endothelial monolayers. This inhibition is 
through downregulation of VCAM-1 expression and decrease of NF-κB activity in endothelial 
cells. 
These studies clearly demonstrated that NO inhibits platelet, leukocyte and monocyte 
adhesion to endothelium.  
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The information presented in sections 1.3.1, 1.3.2, 1.3.3 and 1.3.4 serves as the basis to 
view NO as a vasoprotective molecule. 
1.4 NO INHIBITS THE DEVELOPMENT OF INTIMAL HYPERPLASIA IN 
VASCULAR INJURY 
1.4.1 Mechanisms for the development of intimal hyperplasia 
Intimal hyperplasia is a feature of the healing process following vascular injury. Endothelial 
dysfunction by either physical force (e.g. balloon angioplasty) or by immune mechanisms (e.g. 
allograft rejection) initiates the injury response. Platelets immediately adhere to the injured site 
and aggregate (46). Then leukocytes are recruited to endothelial cells or platelets in the vessel 
wall. P-selectin glycoprotein ligand-1 (PSGL-1) that is expressed on leukocytes interacts with P-
selectin that is expressed on platelets, which facilitates attaching and rolling of leukocytes along 
the vessel wall (47).  β2-integrin Mac-1 (CD11b/CD18) that is expressed on leukocytes and 
ICAM2, an important β-integrin ligand present on platelets (48), also  play an important role in 
mediating leukocyte-platelet interactions (49). Activated platelets secret PDGF, which initiates 
SMC migration and proliferation (50, 51).  Activated leukocytes, monoctyes, macrophages and 
mast cells secret growth factors and cytokines, including PDGF, bFGF, IGF-1, EGF, FGF, TNF-
α, TGF-β and IL-1β (52), which further perpetuate vascular injury. Next, SMC in the tunica 
media layer are stimulated to convert from a contractile nonproliferative phenotype to a synthetic 
proliferative phenotype (53-57) and SMC proliferation and migration from the tunica media 
layer to the intimal layer are initiated. Numerous extracellular stimuli and intracellular signal 
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transduction pathways are proposed to be involved. As mentioned above, following vascular 
injury, many growth factors and cytokines are released, which stimulate SMC to proliferate and 
migrate to the intimal layer. Faries et al. showed that within hours after epigastric vein was 
interposed into femoral artery, PDGF-AA, bFGF, IGF-1, IL-1β, TNF-α were upregulated and 
released and this persisted for 2 weeks (58). Tanaka et al. showed that TNF-α expression was 
remarkably induced in SMC of the tunica medial layer in cardiac allografts (59). IL-1α (60), IL-
1β (61), IGF-1 (62, 63), EGF (64) and bFGF (65) have been shown to enhance SMC 
proliferation in intro. bFGF has also been shown to strongly induce SMC proliferation in 
balloon-injured carotid arteries  from 11.5 % in the control vessel to 54.8% in the bFGF-treated 
counterpart (66). PDGF is a strong mitogen to induce SMC migration in vitro (67).  In balloon 
expansion induced carotid artery injury, PDGF-BB infused arteries showed significant intimal 
hyperplasia compared to the vehicle control (68). IGF-1 has been shown to exacerbate intimal 
hyperplasia in aortic allografts (69). In contrast, inhibition or knockdown of expression of TGF-β 
(70), TNF-α (71, 72) and bFGF (73) significantly suppressed intimal hyperplasia. SMC begin to 
proliferate within 24 hours after injury (74) and SMC migration to the intimal layer is seen 
within 1 to 3 days after injury. Following vascular injury, some of matrix-degrading enzymes, 
such as plasminogen activator (75) and matrix metalloproteinase (76), are upregulated, which 
activates the degradation of cellular matrix and facilitates SMC migration. In contrast, a matrix 
metalloproteinase inhibitor decreased the number of SMC in the intimal layer by 97% compared 
to the vehicle control (76). 
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1.4.2   NO inhibits intimal hyperplasia 
Based on the vasoprotective actions of NO, it is easy to appreciate that exogenous delivery of 
NO would inhibit the development of intimal hyperplasia. In 1993, McNamara et al. 
administered the NO substrate, L-arginine to rabbits following catheter-induced injury to the 
thoracic aorta and observed a drop in intimal hyperplasia by 39% compared to the untreated 
controls. This reduction in intimal hyperplasia was reversed by co-administration of NOS 
inhibitor L-NAME (77). Chemical NO donors such as SPM-5185 (78), NO protein adduct S- 
nitrososerum albumin (79), molsidomine (80), 4-hydroxymethyl-furazan-3-carboxylic acid-2-
oxide (81), or direct inhalation of NO (82), were also shown to inhibit intimal hyperplasia in 
balloon injury models. In 1996, Tzeng et al. delivered human iNOS gene to isolated porcine 
arterial segments by ex vivo gene transfer using a retroviral vector. Although only 1% 
transfection efficiency was obtained, intimal thickening by balloon catheter injury was 
completely inhibited (83). In another balloon injury model, transfection of rat carotid artery 
using an adenoviral vector AdiNOS reduced intimal hyperplasia by >95% in the rat carotid artery 
at 6 weeks post-injury and by 51.8% in the pig iliac artery at 21 days post-injury (84). Not only 
AdiNOS, but AdeNOS transduced carotid artery also showed reduced intimal hyperplasia at 14 
days after injury (85). Moreover, transfection of carotid artery using liposome-DNA plasmid 
with the iNOS gene also suppressed the development of intimal hyperplasia by 81% at 6 months 
after injury (86). Moreover, adenoviral-mediated iNOS expression inhibited intimal hyperplasia 
in the vein grafts by 30% at 21 days after bypass surgery (87). Furthermore, in an aortic 
transplantation model, when aortic allografts from eNOS knockout mice were transplanted into 
wild-type mice, intimal hyperplasia was significantly exacerbated at 30 days after transplantation 
(88). However, overexpression of iNOS by ex vivo AdiNOS gene transfer almost completely 
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prevented the development of aortic allograft arteriosclerosis at 4 weeks after transplantation (88, 
89). In contrast, inhibition of iNOS expression by the iNOS inhibitor L-N6-(l-iminoethyl)-lysine 
(L-NIL) or cyclosporine A (CsA) increased intimal thickening by 57.2% and 65% respectively 
(89). The inhibitory effect of NO on intimal hyperplasia was also shown in the jugular vein 
grafts which were interposed into the carotid artery (90-94). Fulton et al. delivered SNAP locally 
to the vein grafts by mixing SNAP with 30% of pluronic gel and coating the gel on the 
periadventitial vein surface. The local delivery of SNAP resulted in a 36% decrease in intimal 
thickness compared to the gel-only treated control (90) at 28 days after transplantation. Other 
NO donors, spermine/nitric oxide or L-arginine polymer, also showed similar inhibitory effect 
(91, 92). Using the same transplantation model, West et al. showed that AdnNOS gene transfer 
significantly suppressed the acute inflammation that was represented by the suppressed 
expression of the leukocyte marker CD18 and RAM11 at 3 days after transplantation. At 28 days 
post-transplantation, this transient AdnNOS gene transfer decreased intimal thickness by 40% 
compared to the sham or the Adβgal-treated control (94). 
1.5 NO AND CARDIAC ALLOGRAFT ARTERIOSCLEROSIS 
Cardiac allograft arteriosclerosis is characterized by intimal thickening resulting from smooth 
muscle cell proliferation and migration from the tunica media to the intimal layer. It affects the 
entire coronary tree, including both arteries and veins. Based on the extensive studies that show 
that NO inhibits intimal hyperplasia in balloon injury models as well as aorta and vein 
transplantation models, it is reasonable to hypothesize that NO/iNOS plays an inhibitory role on 
the development of cardiac allograft arteriosclerosis. This has been substantiated in cardiac 
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transplantation models. For example, in 1996, Lou et al. showed that supplying 2.5% L-arginine 
in the drinking water to rabbit heart transplantation recipients from day 7 to day 42 after 
transplantation significantly reduced intimal hyperplasia in the donor graft from 44% +/- 4% in 
the non-L-arginine group to 16% +/- 2% in the L-arginine group (p < 0.002) (97).  Kown et al. 
have shown that the incubation of donor hearts in L-arginine polymer solution ex vivo before 
transplantation led to the attenuation of intimal hyperplasia even 90 days after transplantation 
(98). The inhibitory role of NO has also been demonstrated in a previous study where wild-type 
hearts transplanted into iNOS-/- mice exhibited 25% higher intimal thickening compared to the 
wild-type controls at 55 days after transplantation (99). One of the characteristics of cardiac 
allograft arteriosclerosis is the widespread involvement of small, medium and large sizes  
myocardial vessels. In the iNOS-/- recipients, 97% of the graft vessels were affected, which was 
significantly higher than the 79% seen in the wild-type controls (99). Furthermore, commonly 
used immunosuppressants such as FK506, cyclosporine and steroids inhibited the induction of 
iNOS gene (100-102) and this inhibition can be associated with greater allograft arteriosclerosis 
(89). Rapamycin, on the other hand, has similar immunosuppressant activities but does not 
inhibit the expression of iNOS and has been shown to prevent the development of cardiac 
allograft arteriosclerosis (103, 104). 
1.6 NO AND CARDIAC FUNCTION 
Exogenous NO has a concentration-dependent effect on myocardial contractility under basal 
conditions (25). As shown in Figure 1 (25), NO has positive or negative inotropic effects on 
myocardial contractility, which is dependent on NO concentration. Low concentrations of NO 
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improved cardiac contractility both in vitro (105-107) and in vivo (108-110) while high 
concentrations of NO (> 10-7M) exhibit negative inotropic effects. For example, after iNOS 
expression was induced in cardiomyocytes by cytokines or E. Coli. lipopolysaccharide, the 
reactivity of the myocardial muscle changed and myocardial contractility decreased (111-115, 
166, 236). Here, the response to β-adrenergic stimulation was diminished (114, 115) and higher 
cardiac myocyte death was observed (116). In contrast, adding an iNOS inhibitor reversed these 
changes. Overexpression of iNOS in mouse myocardium led to a mild inflammatory cell 
infiltrate, cardiac fibrosis, hypertrophy, dilatation and a high incidence of sudden cardiac death. 
This cardiac phenotype was rescued by specific attenuation of iNOS activity (117). 
 
 
Figure 1 Scheme of the effects of exogenous NO on myocardial contractility under basal conditions. 
 
In contrast to the beneficial effect of iNOS on inhibition of cardiac allograft 
arteriosclerosis during chronic rejection, there is some evidence that iNOS contributes to the 
suppression of cardiac function. In cardiac transplant patients, iNOS was shown to be 
upregulated in cardiomyocytes from initial stage up to 180 days after transplantation (118-120) 
and this induction was correlated to cardiomyocyte apoptosis (118, 119), and systolic and 
diastolic left ventricular contractile dysfunction (120). Myocardial iNOS gene expression level 
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was significantly correlated with the abbreviation of left ventricle electromechanical systole time 
and the fall of left ventricle end-systolic pressure (121). However, in an animal model of cardiac 
transplantation, inhibition of iNOS by aminoguanidine or dexamethasone attenuated acute 
rejection, which was represented by significantly prolonged graft survival (122, 123), reduced 
inflammatory cell infiltrate, interstitial edema and myocyte injury (122, 123), improved 
contractile function of papillary muscle (122, 124) and increased left ventricular diastolic filling 
(125). In addition, when iNOS was knocked out in both donor and recipient mice, cardiac 
allograft survival was significantly increased along with significant reductions in inflammatory 
infiltrate, rejection score, total number of apoptotic nuclei and of apoptotic cardiomyocytes 
during the acute rejection stage (126). Therefore, substantial induction of iNOS in 
cardiomyocytes appears to be toxic to cardiac function. 
Based on these studies, we hypothesize that specific overexpression of eNOS/iNOS in 
smooth muscle or endothelial cells will inhibit the development of cardiac allograft 
arteriosclerosis without suppressing cardiac function. 
1.7 PRELIMINARY DATA: ADCMV-INOS TRANSDUCTION OF DONOR HEART 
Our preliminary data support our hypothesis. In a rat heterotopic heart transplantation model, 
PVG and ACI rats were used as donor and recipient, respectively. Donor hearts were transduced 
using an adenoviral vector AdCMV-iNOS ex vivo for 20 min, and were then transplanted into an 
ACI recipient heterotopically. AdCMV-EGFP was used as a negative control. The adenoviral 
transduction method adopted involved recirculating adenoviral vector in the donor heart as 
described in 2.1.1. The donor graft was harvested at day 4, day 14 or day 28. The grafts were 
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harvested at 28 days after transplantation, embedded in paraffin and the tissue sections were 
stained by verhoeff's Van Geison (vVG) staining. Cardiac allograft arteriosclerosis was 
determined by measuring the extent of vessel occlusion in the graft from the vVG staining slides 
as described in 2.18. Cardiac function was measured for the grafts harvested at 4 and 14 days 
after transplantation using Langendorff perfusion as described in 2.3. 
1.7.1 AdCMV-EGFP mediated universal EGFP expression in the donor graft 
We first determined how the transgene was expressed in the allografts when it was driven by the 
universal promoter cytomegavirus (CMV). Donor PVG rat hearts were transduced by AdCMV-
EGFP, at a dose of 5×109 PFU ex vivo, and then transplanted into ACI recipients. The allografts 
were harvested at 4 days after transplantation. As shown in Figure 2, driven by the universal 
promoter CMV, EGFP was universally expressed in all of the cardiac tissues, including 
vasculature and cardiomyocytes. 
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Figure 2 The CMV promoter led to global expression of EGFP in cardiomyocytes and vasculature when 
donor heart was transduced by AdCMV-EGFP. 
1.7.2 AdCMV-iNOS mediated iNOS expression inhibited cardiac allograft 
arteriosclerosis 
From Figure 2, we can assume that iNOS will be expressed both in cardiomyocytes and blood 
vessels when non-targeting vector AdCMV-iNOS is used to transduce the hearts. 
Using the same transplantation model, donor hearts were transduced by AdCMV-iNOS 
ex vivo, at a dose of 108, 109, or 1010 PFU, prior to transplantation. As shown in Figure 3, at 28 
days after transplantation, 1010 PFU of AdCMV-iNOS significantly suppressed the development 
of cardiac allograft arteriosclerosis while lower titers did not. 
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Figure 3 iNOS expression by Ad-CMV-iNOS inhibits cardiac allograft arteriosclerosis in donor allogrfts.  
Cardiac allograft arteriosclerosis was evaluated by planimetric analysis. At 28 days after transplantation, Ad-CMV-
iNOS transduction with 1010 PFU significantly suppresses CAA. n=1 for each group. *: p<0.05 
1.7.3 AdCMV-EGFP mediated iNOS expression impaired cardiac function 
Next, we determined whether AdCMV-iNOS mediated iNOS expression in the allografts 
impaired cardiac contractility. As shown in Figure 4, at 4 days after transplantation, AdCMV-
iNOS transduction led to a dose-dependent decrease in the left ventricle systolic pressure (LVSP) 
and left ventricle diastolic pressure (LVDP). Moreover, with the titer of 1010 PFU, AdCMV-
iNOS transduction significantly decreased LVSP, LVDP, maximal rate of left ventricular 
pressure development (max dP/dt) or decline (-min dP/dt), heart rate (HR) and coronary flow 
 * 
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(CF), compared to the AdCMV-EGFP control. Mean arterial pressure and left ventricular end 
diastolic pressure were not affected (data not shown). However, at 14 days after transplantation, 
the above cardiac hemodynamic parameters were not significantly different between AdCMV-
iNOS treatment and AdCMV-EGFP control (data not shown). 
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Figure 4 AdiNOS transduction (1010 PFU) impaired cardiac function of donor grafts. 
N=4 for each group. 
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These preliminary data indicate that global expression of iNOS in the donor graft 
inhibited cardiac allograft arterioscleroiss but also suppressed cardiac function. Vascular-specific 
expression of iNOS may avoid the inhibitory effect of excessive NO production on cardiac 
function while preserving its protective effects on vessel injury. 
1.8 VASCULAR-SPECIFIC TARGETING 
Vascular-targeted gene therapy is a promising option for vascular diseases, including tumor 
angiogenesis, atherosclerosis, and the processes leading to intimal hyperplasia (127). However, 
the major limitation in this field has been the lack of endothelial- or smooth muscle cell-specific 
targeting in the vessel wall. To facilitate vascular-specific targeting, different approaches have 
been investigated, including modification of the adenoviral fiber coat proteins (139), insertion of 
a specific peptide into the fiber knob (184) or hexon (185) to permit recognition by specific cell 
receptors, or mixing the vector with tissue-specific antibody (186-188). However, many of these 
are still in the early stage of development with limited success. 
An alternative strategy is to identify promoters capable of directing endothelial- or 
smooth muscle cell-specific expression. The recent development of transgenic mouse technology 
has proven to be a powerful tool to identify cell type-specific promoters since the exogeneous 
promoter and reporter gene is integrated into the host genome. With this technology, several 
endothelial- or smooth muscle cell-specific promoters have been identified in the past decade. 
The endothelial cell-specific promoters include the murine Tie2 promoter with a 1.6 kb enhancer 
(128), the murine Tie2 promoter with a 10 kb enhancer (128), the human intercellular adhesion 
molecular 2 promoter (ICAM2, -292 ~ +44 bp) (129), the human von Willebrand factor promoter 
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with enhancer (vWF, -487 ~ +246 bp) (130), the murine vascular endothelial cadherin promoter 
with enhancer (-2486 ~ +24 bp) (131), the murine preproendothelin-1 promoter with small 
enhancer (5.9kb 5’ flank region + first exon and first intron) (132), and the murine 
preproendothelin-1 promoter with large enhancer (9.2kb 5’flank region + first exon and first 
intron) (133) (9.2 kb 5’flank region + first exon and first intron). The smooth muscle cell-
specific promoters include rat smooth muscle myosin heavy chain promoter with large enhancer 
(SMMHC, -4229 ~ +11600 bp) (134), rabbit smooth muscle myosin heavy chain promoter 
(SMMHC, -2305 ~ -4 bp) (135) and murine smooth muscle 22α promoter (SM22α, -441 ~ +41 
bp) (136). The vascular-specificity of these promoters, was established in transgenic mice (128-
133). Another endothelial cell-specific promoter, the human fms-like tyrosine kinase-1 promoter 
(Flt-1, -748 ~ +284 bp) (137), was identified in vitro by serial deletions of the promoter region of 
the Flt-1 gene. The specificity of this promoter was also confirmed in two other studies in vitro 
and in vivo (138, 139), in which the Flt-1 promoter was utilized in adenoviral vectors. 
In this study, we proposed to identify a smooth muscle or endothelial cell-specific 
promoter for vascular-specific expression of iNOS in the heart. 
1.9  GENE DELIVERY SYSTEM 
Based on the protective effects of NO on vascular injury and the destructive role of NO at high 
level on cardiac function, we propose to develop a gene delivery system to express iNOS 
specifically in smooth muscle or endothelial cells, but not in cardiomyocytes. Which gene 
delivery system can achive this? We first chose to contruct an adenoviral vector. 
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1.9.1 Adenoviral vector 
For the past decade, viral and nonviral vectors have been the most widely used tools to deliver 
transgene into tissue, among which adenoviral vectors are the most popular gene delivery 
vectors. Adenoviruses are well characterized biochemically and genetically. Decades of studies 
have produced a relatively clear picture of the viral life cycle and the functions of most of the 
viral proteins (140). Adenoviruses have been modified with the deletion of some or all of the 
viral genes to accommodate foreign genes with a wide range of sizes. The E1, E3 deleted 
adenovirus can accommondate foreign genes up to 7~8kb. The most recent generation of 
adenovirus, gutless adenovirus, can carry foreign genes up to 38kb. In contrast, adeno- 
associated viruses can accommondate foreign genes up to 4.5kb. With the deletion of viral genes, 
the immune response in the host is also significantly reduced. Adenoviruses are easily 
manipulated and can be grown to high titers (141). They infect both resting and dividing cells 
(142, 143) and transduce most types of cells with high efficiency while non viral vectors are 
limited by low transfection efficiency. Unlike retroviruses, adenoviruses do not integrate into 
host genome and long-term therapeutic safety is less of a concern.  
Our preliminary data also supports the notion that an adenoviral vector designed for 
vascular-specific targeting would be a good choice to inhibit cardiac allograft arteriosclerois 
while preserving cardiac function. Considering these advantages, we decided to construct 
adenoviral vectors using cell type-specific promoters to restrict iNOS expression to the vessel 
wall, as shown in Figure 5. 
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Figure 5 Structure of adenoviral vector with vascular-specific promoter and the iNOS gene. 
1.9.2 Vascular-specific iNOS inducible transgenic mice 
Although adenoviruses have many advantages, great variation, poor reproducibility, and lack of 
control of transgene expression levels and duration limit their applicability. Other approaches 
may be required to test our hypothesis. For example, inducible regulation of transgene 
expression in a transgenic animal model could circumvent these limitations and may serve as a 
good alternative option to investigate the therapeutic effect of transgene (144, 145). 
 
Poly A 
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Adenoviral genes (E1/E3 deleted) 
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Figure 6 GeneSwitch system is composed of two DNA plasmids: regulatory plasmid pSwitch and responsive 
plasmid pGene/V5-his. 
 
An advantage of the inducible system is that transgene is silent until a ligand is given to 
induce its expression or vice versa. Based on ligand type, there are four inducible regulation 
systems currently available: tetracycline (Tet on/off), ecdysone (Complete Control), mifepristone 
(GeneSwitch) and RL1 (RheoSwitch).  These systems can be best explained by describing two 
DNA plasmids: a regulatory and a responsive DNA plasmid. For example, in the GeneSwitch 
system (Figure 6), pSwitch is the regulatory plasmid and pGeneV5/His is the responsive 
plasmid. Transgene (iNOS) would be inserted into the multiple cloing site of the responsive 
plasmid between the E1A TATA minimal promoter and BGH pA sequence. The DNA plasmid 
pSwitch regulates the expression of the Switch protein, which is composed of two domains: a 
ligand-binding domain and a response element-binding domain. Only after the ligand, 
mifepristone, binds to its ligand-binding domain, does a conformational change occure in the 
iNOS 
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Switch protein. This change promotes its element-binding domain binds to an element-binding 
sequence GAL4 USA which is located upstream of the transgene in the pGeneV5/His DNA 
plasmid. This binding activates the transcription and translation of the transgene. The regulation 
of inducible transgene expression in GeneSwitch is shown in Figure 7. The level and duration of 
the transgene expression can be regulated by the dose and time of the ligand administration 
(146). Cell-type specific expression of the transgene can also be achieved by using a cell-type 
specific promoter to drive the Switch expression (146-149). 
In the inducible system, it is critical whether the transgene can be tightly regulated. Tet 
on/off system exhibited leaky expression of the transgene (150, 151). In contrast, GeneSwitch 
has been reported to regulate transgene stringently in vitro and in vivo (146, 148). As shown in 
Table 1 (from Invitrogen Catalog 2004), Invitrogen Corp. compared the two systems and 
concluded that the leaky expression of GeneSwitch is much lower than that of Tet-on in HEK293 
cells. As a stringent test of leakiness in vivo, Osterwalder et al. inserted TeTxLC, a potent 
neurotoxin, into GeneSwitch and made a transgenic Drosophila. Expression of TeTXLC results 
in complete embryonic paralysis and failure to hatch Drosophila offspring. Their results showed 
that without mifepristone induction, embryonic survival of the TeTxLC-transgenic Drosophila 
was 77.8%, which was similar to the EGFP-transgenic control (71.5%). With 1µg/ml 
mifepristone, the survival rate of TeTXLC-transgenic Drosophila dropped to 7% (Figure 8, 146). 
These data solidly validated that the transgene is tightly regulated in GeneSwitch system. 
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Table 1 Comparison of regulated mammalian expression systems (From Invitrogen Catalog 2004). 
system Basal 
expression 
Induced 
expression level 
Response time to 
maximal 
Transgenic 
application 
Tet-Regulated 
Expression 
Low Highest 24hrs Suitable 
Flp-in Tet-Regulated 
Expression 
Lower High 24~48 hrs Suitable 
GeneSwitch System Lowest Low 24hrs Suitable 
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Figure 7 Regulation of transgene inducible expression by GeneSwitch. 
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Figure 8 GeneSwitch exhibited low basal expression in transgenic drosophila. 
 
Besides near absent basal transgene expression, GeneSwitch demonstrated several other 
advantages. First, the regulatory protein Switch is a fusion protein and composed of a ligand 
binding domain and a response element binding domain. One universal promoter, herpes simplex 
virus thymidine kinase mimimal promoter and its upstream GAL4UAS sequence, regulates the 
expression of Switch universally. To achieve vascular-specific expression of iNOS, we will 
replace this universal promoter with a smooth muscle or endothelial cell-specific promoter. In 
contrast, in RheoSwitch, the regulatory protein is composed of two proteins, whose expression is 
manipulated by two universal promoters. For cell type-specific expression of iNOS, we need to 
substitute the vascular-specific promoter for these two promoters. Therefore, modification of the 
GeneSwitch system is easier. Second, the ligand mifepristone in GeneSwitch, also named as 
71.5% 
7% 
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RU486 (a French name), is a synthetic steroid. The combinational use of 
mifepristone/misoprostol was approved as an abortion drug by FDA in 2000. Mifepristone binds 
to progesterone receptor as an antagonist of progesterone.  Studies have demonstrated that 
progesterone neither affected the development of intimal hyperplasia in a balloon-injured carotid 
artery (152) nor the progress of arteriosclerosis in coronary artery (153-155) in rat, rabbit and 
monkey models regardless of gender. Therefore, we assume that a progesterone antagonist, 
mifepristone, will not affect the development of intimal hyperplasia in our heart transplantation 
model. Third, mifepristone does not affect cardiac function. Lutucuta S et al. (156) showed that 
administration of mifepristone into wild-type or geneswitch transgenic mice for 16 days did not 
significantly change cardiac function, including heart rate, left ventricular ejection fraction, left-
ventricular end-diastolic diameter, left-ventricular end-systolic diameter, fractional shortening, 
aortic maximum velocity, circumference per second, deceleration time, mitral valve inflow E 
velocity, mitral valve inflow E/A ratio and velocity of circumferential fiber shortnening. 
Mifepristone also did not induce morphological change, including body weight, left ventricular 
mass, left ventricular mass/body weight ratio, posterior wall thickness and septal thickness. 
Therefore, we assume that mifepristone will not affect cardiac function in the donor heart. From 
these studies, we propose that GeneSwitch is an optimal option for our cardiac allograft 
arteriosclerosis project. 
Considering the possible failure of adenoviral vector for vascular-specific expression of 
iNOS, as a back up strategy, we employed the GeneSwitch system to develop iNOS inducible 
transgenic mice. iNOS transgenic mice have not been successfully generated yet because 
transgenic mice with constitutively expressed iNOS do not survive to the adult stage (117). 
Inducible iNOS transgenic mice serve a better model to determine the effect and function of 
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iNOS. We propose to use the iNOS inducible transgenic mice as donor and determine the 
efficacy of vascular-specific iNOS overexpression on the suppression of cardiac allograft 
arteriosclerosis and the effects on cardiac function. 
1.10 ENOS TRANSGENIC MICE 
We hypothesize that smooth muscle- or endothelial-specific NOS (eNOS or iNOS) expression 
will inhibit cardiac allograft arteriosclerosis without affecting cardiac function. To achieve iNOS 
specific expression in smooth muscle or endothelial cells, we proposed to develop two gene 
delivery systems: adenoviral vector and vascular-specific iNOS inducible transgenic mice. In 
case these approaches fail, we imported eNOS transgenic mice from Dr. Rini De Crom 
(Netherland) as a backup strategy to test our hypothesis. In this eNOS transgenic mice line, the 
human eNOS promoter regulates the human eNOS endothelial-specific expression (159). The 
schematic structure of this transgenic mice transgene is shown in Figure 9. 
 
Figure 9 Schematic structure of eNOS transgenic mice. 
 
eNOS has been shown to play a protective role in vascular injury. Overexpression of 
eNOS in balloon-injured carotid artery by administration of sendi virus/liposome-DNA plasmid 
complex (157) or by AdeNOS gene delivery (85) significantly suppressed intimal hyperplasia at 
14 days after injury. In a murine aortic transplantation model, aortic allograft arteriosclerosis was 
heNOS promoter heNOS (exon and intron) 
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accelerated in aortic allografts of eNOS knock-out mice (88). Iwata A et al. showed that 
liposome-DNA-mediated gene transfer of eNOS into donor heart decreased ischemia-reperfusion 
injury by inhibiting NF-κB activation, reduced expression of adhesion molecules ICAM-1 and 
VCAM-1 as well as leukocytes infiltration in the donor heart (158). The consequence of eNOS 
overexpression in eNOS transgenic mice on atherosclerosis has been elucidated by van Haperen 
et al. (159). Crossing the eNOS transgenic mice with apo E knockout mice resulted in a 
suppression of the atherosclerotic lesion formation. We hypothesize that endothelial-specific 
overexpression of eNOS would inhibit cardiac allograft arteriosclerosis. 
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2.0  MATERIALS AND METHODS 
2.1 EX VIVO TRANSDUCTION OF DONOR HEART BY ADENOVIRAL VECTOR 
We adopted two methods to transduce donor heart using adenoviral vector: one is to recirculate 
the adenoviral vector in donor heart at 4°C; the other is to inject adenoviral vectors into donor 
heart and incubate for two hours at 4°C in a static system. 
2.1.1 Ex vivo transduction of donor heart by recirculating adenoviral vector in donor 
heart 
Donor hearts were arrested with cold cardioplegia solution (University of Wisconsin), then 
perfused with 5 ml of cold (4°C) UW solution containing varying concentrations from 2×107 to 
2×1010 pfu adenoviral vector.  The perfusate was directed into the aortic root for 20 minutes 
using a recirculating circuit that collects the viral effluent from the coronary sinus to the 
pulmonary artery and allowed for the continuous reperfusion of the vector in the coronary 
vessels. The perfusion pressure was kept at 70 cm H2O, and the graft and the perfusate was kept 
at 4°C during the infection. This infection technique provides homogenous transfer throughout 
the ventricular mass and additionally leads to high efficiency of transfer to the coronary artery 
endothelial cells. 
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2.1.2 Ex vivo transduction of donor heart by single injection of adenoviral vector into 
donor heart 
In a syngeneic heart transplantation model, PVG rats (200~250g, Harlan Sprague Dawley) were 
used as both donor and recipient. The abdomen and chest of the donor rat were opened and the 
heart was perfused with 10ml of Lactated Ringer’s solution (Rxveterinary Products, Porterville, 
CA). The inferior vena vein, superior vena vein, left lung, right lung, and the three river veins 
were ligated. The adenoviral vectors, AdFlt-1-lacZ or AdICAM2-lacZ (dose of 1010PFU) were 
diluted in Lactated Ringer’s solution to make the total volume 1000 μl and injected slowly into 
the coronary arteries through the brachiocelephilic artery. After injection, the aortic root and the 
pulmonary artery were clamped and the donor heart was harvested. The donor heart was kept in 
the Lactated Ringer’s solution at 4ºC for two hours. Next, it was transplanted into a syngeneic 
PVG rat heterotopically as described in 2.2. 
2.2 RODENT HETEROTOPIC HEART TRANSPLANTATION 
Male PVG (RT1-Ac) and ACI (RT1-Aa) rats, 2-3 months old and weighing 200-250 grams, were 
purchased from Harlan Sprague Dawley (Indianapolis, IN). PVG and ACI rats were used as 
donor and recipient, respectively. Heterotopic heart transplantation was performed as previously 
described by Ono and Linsay (160). Briefly, after induction of general anesthesia with inhaled 
isofluorane, a laparotomy was performed under clean conditions.  The donor heart was 
heterotopically transplanted into the recipient by end-to-side anastomoses of the aorta and the 
pulmonary artery to the abdominal aorta and inferior vena cava, respectively using 10/0 
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monofilament sutures. The abdominal wall was closed by continuous suture using 4-0 silk after 
hemostasis was obtained. After transplantation, recipient rats received a 10 day course of 
cyclosporine (CsA: 100mg/ml, Sandoz Pharmaceuticals, Holzkirchen, Germany) at a dose 
5mg/kg/day, IP (intraperitoneal) injection. Graft function was assessed by daily palpation of 
beating. 
The mouse heterotopic heart transplantation was performed in a similar manner. 
2.3 MEASURRMENT OF CARDIAC FUNCTION USING LANGENDORFF 
PERFUSION 
Langendorff perfusion is a well-accepted method to measure cardiac function in rodents. In this 
preparation, the heart was perfused using a physiologic solution at a constant physiologic 
preload. Specifically, the rats were anesthetized with pentobarbital (50mg/kg IP) and anti-
coagulated by injection of heparin (1000U/kg IV). The graft was excised and immediately 
submerged in iced Krebs-Henseleit solution, then mounted on an isolated heart perfusion 
apparatus with a retrograde perfusion pressure of 80 cmH2O. The left atrium was cannulated and 
antegrade perfusion was started at a constant pressure of 10 cm H2O. The solution was kept at 
37°C and bubbled with 95%O2-5%CO2. A fluid-filled latex balloon was inserted into the left 
ventricle and connected to a transducer for measurement of left ventricle pressures. The graft 
was permitted to stabilize for 15 minutes, at which time cardiac performance was measured, 
including heart rate (HR), left ventricle systolic pressure (LVSP), left ventricular developed 
pressure (LVDP), left ventricle end systolic pressure (LVESP), arterial pressure (AP), maximal 
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rate of left ventricular pressure development (+dP/dt max), maximal rate of left ventricular 
pressure decline (-dP/dt min), and coronary flow (CF). 
2.4 DNA PLASMIDS AND ADENOVIRUSES 
The DNA plasmids pTie2SE-lacZ and pTie2LE-lacZ were kindly provided by Dr. Thomas N. 
Sato (University of Texas Southwestern Medical Center), and are referred to the original name 
used by this laboratory pHHSDKXK and pT2HLacZpA1I.7, respectively. The ICAM2, vWF, 
Flt-1 and cytomegalovirus (CMV) promoters were constructed in E1-deleted adenoviruses 
referred to as AdICAM2-lacZ, AdvWF-lacZ, AdFlt-1-lacZ, and AdCMV-lacZ, respectively. The 
Flt-1 promoter was also constructed in a DNA plasmid upstream of the luciferase gene, referred 
to as pFlt-1-luc. The four adenoviruses and the DNA plasmid pFlt-1-luc were kindly provided by 
Dr. Andrew H Baker (University of Glasgow) with the permission of the original authors. The 
Tie2SE, ICAM2, vWF, and CMV promoters were constructed in DNA plasmids upstream of the 
FretMT gene and are referred to as pTie2SE-FretMT, pICAM2-FretMT, pvWF-FretMT, and 
pCMV-FretMT, respectively. FretMT is a fusion protein that is composed of Enhanced Cyan 
Fluorescent Proteins (ECFP) human metallothionein (MT) and Enhanced Yellow Fluorescent 
Proteins (EYFP) genes. The four DNA plasmids were kindly provided by Dr. Bruce Pitt 
(University of Pittsburgh). The Rous sarcoma virus promoter (RSV) was constructed in a DNA 
plasmid upstream of the luciferase gene and is referred to as pRSV-luc. The DNA plasmid 
pCMV-EGFP was purchased from Clontech (Mountain view, CA) with the original name of 
pEGFP N1. The adenovirus AdCMV-EGFP was kindly provided by Dr. Andrew Gambotto 
(University of Pittsburgh). The DNA plasmid pSMMHCL-luc was kindly provided by Dr. Gary 
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K. Owens (University of Virginia) with the original name of pPI Myo-luc. The DNA plasmid 
pSMMHCS-EGFP was kindly provided by Dr. Wolfgang M. Franz (University of Lübeck, 
Germany) with the original name of pSMHC-EGFP. The GeneSwitchTM core kit, including the 
DNA plasmids pSwitch, pGene/V5-hisA, pGene/V5-hisB, pGene/V5-hisC and pGene/V5-his-
lacZ were purchased from Invitrogen. The adenoviral vectors AdSwitch and Ad5xGal4-luc were 
kindly provided by Dr. Ramesh A Bhat (Weyth Research). 
2.5 CONSTRUCTION OF ADENOVIRAL VECTOR ADFLT-1-INOS, ADICAM2-
INOS AND ADTIE2-INOS 
To make E1, E3 deleted adenoviral vectors, shuttle DNA plasmids with the insertion of cell type-
specific promoter Flt-1, ICAM2, or Tie2SE and the target gene iNOS were constructed first. The 
adenoviral shuttle plasmid pAdlox (SwaI modified) used for the construction of E1/E3 deleted 
adenoviral vector was kindly offered by our collaborator, Dr. Andrea A. Gambotto (U. 
Pittsburgh). The CMV promoter in this plasmid was replaced by the endothelial-specific 
promoter Flt-1, ICAM2 or Tie2SE. To construct the shuttle DNA plasmid pAdloxFlt-1, the Flt-1 
promoter was subcloned from viral DNA extracted from adenovirus AdFlt-1-lacZ. Fifty 
microliters of AdFlt-1-lacZ (109 PFU) was degraded in 150 μl of protein degrading buffer with a 
final concentration of 0.1% SDS and 0.03 μg/μl protein kinase K at 37°C for 1h. Next, the viral 
DNA was extracted using Qiaquick gel extraction kit (Qiagen, Valencia, CA). Two hundred 
microliters of the degrading mixture was incubated with 600 μl of QG buffer on heat-block at 
50°C for 5min, was then applied to a Qia quick column. The column was washed using 750 μl of 
PE buffer and spun for 30 sec. The liquid was cleaned out and the residual of PE buffer in the 
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column was spinned down for 2 more min. The column was inserted into a new microfuge tube 
and the viral DNA was eluted using dH2O. Thirty-five microliters of dH2O was preheated to 
70°C and added into the column. The column was incubated on heat-block at 70°C for 2 min, 
then spun down for 2 min and the viral DNA pAdFlt-1-lacZ was collected. 
The Flt-1 promoter was amplified from pAdFlt-1-lacZ by PCR using 5’ primer 
CCCCTCGAGCTTCTAGGAAGCAGAAGACTGAGGA and 3’ primer 
CAACAAGCTTGTGAGCGCGACGCGGCCTGCTCGCC. The PCR condition is 94°C, 5 min; 
94°C, 45 sec, 60°C, 30 sec, 72°C, 80 sec, 30 cycles; 72°C, 7 min. The PCR product of the Flt-1 
promoter was separated from other non-specific bands by running 0.9% of agarose gel and 
extracted using QIAquick gel extraction kit. The Flt-1 promoter was codigested by restriction 
enzyme XhoI (5’) and HindIII (3’) (New England Biolabs, IpSwich, MA) and the Flt-1 promoter 
fragment was ready to be subcloned. If no specific indication, all of the restriction enzymes used 
in this thesis were purchased from New England Biolabs. The CMV promoter was removed from 
the DNA plasmid pAdlox by XhoI (5’) and HindIII (3’). Then the Flt-1 promoter fragment was 
ligated with the pAdlox fragment by T4 DNA ligase (Rapid ligation kit, Gene Choice, Frederick, 
MD) and the DNA plasmid pAdloxFlt-1 was constructed (Figure 10). 
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Figure 10 Construction of DNA plasmids pAdlox-Flt-1 and pAdloxFlt-1-iNOS from pAdlox (Swa I). 
 
To construct the shuttle plasmid pAdloxFlt-1-iNOS, the DNA plasmid pAdloxFlt-1 was 
digested using restriction enzyme Sma I and Hind III sequentially and then incubated with 
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alkaline phosphatase (Roche Diagnostics, Indianapolis, IN) at 37°C for 60 min to remove the 
phosphate group from the 5’ end to prevent self-ligation. To release the human iNOS cDNA 
from the DNA plasmid pcDNA3-iNOS, pcDNA3-iNOS was digested using XbaI. Then the DNA 
fragment was blunted by DNA end-repair enzymes T4 DNA polymerase and T4 polynucleotide 
kinase with the supply of dNTP and ATP (End-it DNA End-Repair kit, Epicentre, Madson, WI) 
at room temperature for 45 min. Next, the linearized DNA fragment was digested with Hind III 
and the 3.5 kb human iNOS cDNA was released.  The vector pAdlox Flt-1 fragment was ligated 
with the insertion of human iNOS fragment by T4 DNA ligase at room temperature for 30 min 
and finally pAdloxFlt-1-iNOS was constructed (Figure 10). 
AdICAM2-iNOS and AdTie2-iNOS were generated similarly. 
2.6 CELL CULTURE 
Rat smooth muscle cells were isolated from Lewis rat (Harlan Sprague-Dawley, Indianapolis, 
IN) aortic strips as previously described (18). Cultured cells had the characteristic “hills and 
valleys” appearance and were routinely more than 95% pure by SMC α-actin staining (data not 
shown). Cells were grown in Dulbecco's Modified Eagles medium (low glucose)/Ham's F12 (1:1 
vol:vol; BioWhittaker; Walkersville, MD) supplemented with 10% FBS, 100 U/mL penicillin, 
100 µg/mL streptomycin, and 4 mmol/L L-glutamine.  The cells from passages 3 to 7 were used 
for transfection. Bovine aortic endothelial cells (BAEC) were purchased from BioWhittaker and 
were cultured in EGM2-MV medium. Rat hepatocytes were isolated from Lewis male rats (200-
250g, Harlan Sprague-Dawley) by a modification of the in situ collagenase perfusion technique 
of Seglen (19). Hepatocytes were plated onto gelatin-coated dishes and maintained using cell 
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culture medium consisting of Williams’ medium E (GIBCO, Carlsbad, CA) supplemented with 
L-arginine (0.5 mM), insulin (1 μM), Hepes (15 mM), L-glutamine, penicillin, streptomycin, and 
10% low endotoxin calf serum (Hyclone, Logan, UT). HEK293 cells were kindly offered by Dr. 
Andrea Gambotto (University of Pittsburgh). HEK293 cells were cultured in Dulbecco's 
Modified Eagles medium (high glucose, Cellgro, Herndon, VA) supplemented with 10% FBS 
and 100 U/mL penicillin, and 100 µg/mL streptomycin. 
2.7 TRANSFECTION OF CELLS USING LIPOSOME-DNA PLASMIDS COMPLEX 
The transfection conditions of BAEC, rat smooth muscle cells, rat hepatocytes and HEK293 cells 
were optimized for each cell line. 
2.7.1 Transfection of BAEC and rat hepatocytes 
To transfect BAEC and rat hepatocytes, cells were plated in 12-well plates at a density of 5×104 
cells/well. 1.6 μg of DNA plasmids was mixed with 100 μl of Opti-MEM (Invitrogen, Carlsbad, 
CA). Five microliters of Lipofectin (Invitrogen) were mixed with 100 μl of Opti-MEM and 
incubated for 35 minutes at room temperature. The DNA plasmids were then mixed with 
Lipofectin and incubated for 15 minutes at room temperature. Next, 800 μl of Opti-MEM was 
added into the mixture and mixed gently. The transfection mixture was added into cells and the 
cells were incubated at 37°C for 5 hours.  The transfection mixture was aspirated and the cells 
were incubated in normal culture medium for 48 hours. Finally, reporter gene expression was 
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determined by checking green fluorescence, performing X-gal staining, or measuring luciferase 
activity as appropriate to each reporter construct assessed as described below. 
2.7.2 Transfection of primary rat SMC 
To transfect primary rat smooth muscle cells, cells were plated in 12-well plates at a density of 
5×104 cells/well. 1.6 μg of DNA plasmids was mixed with 100 μl of Opti-MEM. Four 
microliters of Lipofectamine 2000 (Invitrogen) was mixed with 100 μl of Opti-MEM and 
incubated for 5 minutes at room temperature. Then the DNA plasmids were mixed with 
Lipofectamine 2000 and incubated for 20 minutes. Next, 800 μl of Opti-MEM was added into 
the mixture, mixed gently, and the total 1000 μl of mixture was added to the cells. After 6 hours, 
FBS was added into the transfection medium to a final concentration of 10%, and the cells were 
incubated for 16 hours. The transfection medium was replaced by the cell culture medium. 
Fourty-eight hours later, the cells were analyzed for reporter gene expression as described below. 
2.7.3 Transfection of HEK293 cells 
To transfect HEK293 cells, the cells were plated in 12-well plates at a density of 5×105 
cells/well. Next, 3.2 μl of TransIT ExpressTM (Mirus Bio, Madison, WI) was mixed with 40 μl of 
Opti-MEM and incubated at room temperature for 15 minutes. Then, 0.4 μg of DNA plasmids 
was added into the mixture and incubated for 15 minutes. Next, 460 μl of Opti-MEM was added 
into the mixture and the total 500 μl of the mixture was added to the cells for transfection. One 
hour later, 500 μl of the cell culture medium was added into the transfection mixture and 
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incubated for 24 hours. The transfection medium was replaced by fresh culture medium. Thirty-
six hours later, reporter gene expression was assessed as described below. 
2.8 DETECTION OF REPORTER GENE EXPRESSION 
FretMT expression was detected by green fluorescence using an Olympus Provis AX70 
microscope (Tokyo, Japan) and the percentage of the cells demonstrating green fluorescence was 
calculated. LacZ expression was detected by X-gal staining (beta-galactosidase staining kit, 
Mirus Bio) according to manufacturer’s protocol, and the percentage of the cells with blue 
staining was calculated. Luciferase activity was measured using a Luciferase assay system 
(Promega, San Luis Obispo, CA). Briefly, cells were washed with PBS for three times and 150 
μl of reporter lysis buffer was added (for a 12-well plate). Cells were lysed at room temperature 
for 15 minutes by shaking. The cell lysates were then microcentrifuged (13000 rpm × 5 min) and 
20 μl of the clear supernatants were added to 100 μl of luciferase assay buffer (Promega). The 
activity was measured in an AutoLumat LB 953 Luminometer (Berthold, Bad Wildbad, 
Germany) over a 30-second period.  Luciferase activity was normalized to the amount of protein 
and expressed as relative luciferase activity (LU/μg protein). 
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2.9 EX VIVO TRANSDUCTION OF RAT AORTA, CARDIAC AND SKELETAL 
MUSCLE 
Rat aortas were cut into 5 mm-long strips. Rat cardiac and skeletal muscles were also cut into 3 
mm × 3 mm pieces. The aorta, cardiac muscle, and skeletal muscle samples were washed with 
Opti-MEM medium three times. 2×109 PFU of AdFlt-1-lacZ, AdICAM2-lacZ, AdvWF-lacZ, 
AdCMV-lacZ, or AdCMV-EGFP were diluted in 200 μl of Opti-MEM. The tissues were rinsed 
in the adenoviral mixture and incubated at 37°C for 2 hours. The tissues were then washed with 
PBS three times and rinsed in 5 ml of culture medium (Dulbecco's Modified Eagles medium 
(low glucose)/Ham's F12, 1:1 vol:vol; BioWhittaker; Walkersville, MD) supplemented with 10% 
FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, and 4 mmol/L L-glutamine) in 30-mm 
dishes. The tissues were incubated in cell culture incubator for 72 hours with daily changes of 
culture medium. 
2.10 X-GAL STAINING OF ADENOVIRAL VECTOR TRANSDUCED RAT AORTA, 
CARDIAC AND SKELETAL MUSCLE 
Seventy-two hours after culture, rat aortas, cardiac and skeletal muscles were fixed in 2% of 
paraformaldehyde, washed with PBS and stained with the X-gal staining reagents (Mirus Bio) in 
a humid dark box for 16 hours. Then the stained tissues were frozen in OCT compound (Sakura 
Tissue-Tek, McGaw Park, IL,) and cryostat sections were cut to a thickness of 6 μm. At every 10 
cuts, the specimen was collected and checked for positive staining using a reflected light 
differential interference contrast microscope (Olympus Provis AX70, Tokyo, Japan). 
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2.11 TRANSFECTION OF HEK293 CELLS USING GENESWITCH 
To determine the induction of lacZ gene by GeneSwitch, HEK293 cells were seeded in a 12-well 
plate at a density of 3.5×106 cells/well. Eight microliters of transfection reagent TransIT 
ExpressTM (Mirus Bio) were gently mixed with 100 μl of Opti-MEM and incubated for 15 min at 
room temperature. 0.25 μg of DNA plasmid pSwitch and 1μg of pGenev5His-lacZ were added 
into TransIT ExpressTM mixture, gently mixed and incubated for 15 min at room temperature. 
Subsequently, 400 μl of Opti-MEM was added into the mixture, mixed gently and the total 
volume of 500 μl of the transfection mixture was added into HEK293 cells and incubated for 1 
hr. Then 500 μl of the cell culture media was added into cells and incubated for 24 hrs. Next, the 
cells were induced by the ligand mifepristone at a concentration gradient from10-12 M to10-7 M 
for 48 hrs. Finally, X-gal staining was performed to detect the lacZ expression. Pictures were 
taken for the cells using a reflected light differential interference contrast microscope (Olympus 
Provis AX70, Tokyo, Japan) and the percentage of blue stained cells was calculated using 
Metamorph software. 
To detect the iNOS expression, the method is the same as above, but the DNA plasmid 
pGeneA-iNOS replaced pGenev5His-lacZ. Twenty-four and 48 hrs after mifepristone induction, 
Greiss assay was applied to measure the nitrite level in the cell culture media. Cells were 
harvested and western blot was performed to detect the iNOS expression. A rabbit anti-iNOS 
polyclonal antibody (BD Biosciences, San Jose, CA) was used to detect the iNOS expression. 
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2.12 HARVESTING FIBROBLAST CELLS FROM MOUSE TAIL AND CULTURE 
Wild-type mice C3B6F1 were purchased from Charles River (Wilmington, MA). Mouse tail 
(3~5 cm long) was sterilized with betadine and vortexed for 3~5 sec in 100% ethanol for 
sterilization and infused in sterilized PBS. The tail was cut into 5mm long small pieces. Each 
piece was split in the middle to expose the connective tissue. The bone was removed and the 
connective tissue side was attached to the bottom of a 6-well culture dish. The cell culture 
medium (Dulbecco’s Modified Eagle Medium (high glucose, Invitrogen) supplied with 20%  
FBS and 1% antimyocotic (Invitrogen)) was added and changed daily. Fibroblasts started to 
migrate out of the connective tissue within 3 days and continued to migrate and proliferate in the 
dish for 10 days. 
2.13 TRANSFECTION OF C3B6F1 MOUSE TAIL FIBROBLASTS USING DNA-
LIPOSOME MIXTURE OR BY ELECTROPORATION 
To optimize the transfection effiency in primary adult mouse tail fibroblast, different transfection 
reagents were used to transfect fibroblast that was extracted from C3B6F1 mice tail, including 
lipofectamine LTX with Plus (Invitrogen), lipofectamine 2000 with Plus (Invitrogen), 
GenePORTER (Genelantis, San Diego, CA), TransIT express (Mirus Bio) and Fugene 6 (Roche 
Diagnostics). The fibroblasts were also transfected by electroporation. 
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2.13.1 Transfection of primary mice tail fibroblasts with lipofectamine LTX and Plus 
Primary fibroblasts were seeded in a 24-well plate at a density of 5×104 cells/well. 0.5μg of DNA 
plasmid pCMV-lacZ was gently mixed with 100 μl of Opti-MEM. 0.5 μl of Plus was added, 
gently mixed and the mixture was incubated at room temperature for 10 min. Next, 1.25 μl of 
lipofectamine LTX was added, gently mixed and the mixture was incubated at room temperature 
for 30 min. 150 μl of Opti-MEM was added into mixture, mixed gently, and the total 250 μl of 
the DNA-liposome mixture was added into the cells and incubated for 6 hrs. Next, 250 μl of 
DMEM medium (Dulbecco’s Modified Eagle Medium (high glucose, Invitrogen)) with 40%  
FBS was added into cells, mixed with the transfection medium and the cells were incubated for 
16 hrs. Subsequently, the tranfection mixture was aspirated and fresh cell culture media was 
added to incubate cells for 48 hrs. Finally, X-gal staining was performed to detect the lacZ 
expression. 
2.13.2 Transfection of primary mice tail fibroblasts with lipofectamine 2000 and Plus 
Primary fibroblasts were seeded in a 24-well plate at a density of 5×104 cells/well. 0.8 μg of 
DNA plasmid pCMV-lacZ was gently mixed with 50 μl of Opti-MEM. Eight microliters of Plus 
was added, gently mixed and the mixture was incubated at room temperature for 15 min. At the 
same time, two microliters of lipofectamine 2000 was mixed with 50 μl of Opti-MEM and 
incubated for 15 min. Next, the DNA and lipofectamine 2000 mixture were combined together, 
mixed gently and incubated for 15 min. 150 μl of Opti-MEM was added, mixed gently, and the 
total 250 μl of transfection media was added into cells and the cells were incubated for 6 hrs. 
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Subsequently, the tranfection mixture was aspirated and 500 μl of DMEM with 20% FBS was 
added into cells and the cells were incubated for 48 hrs. Finally, X-gal staining was performed to 
detect the lacZ expression. 
2.13.3 Transfection of primary mice tail fibroblasts with GenePORTER 
Primary fibroblasts were seeded in a 24-well plate at a density of 5×104 cells/well. Two 
micrograms of the DNA plasmid pCMV-lacZ was gently mixed in 125 μl of DMEM. Five 
microliters of GenePORTER was mixed with 125 μl of DMEM and incubated for 3~5 min. 
Next, the DNA and GenePORTER mixture were mixed gently and was incubated for 40 min at 
room temperature. The DNA-liposome mixture was added into cells and the cells were incubated 
for 5.5 hrs. Subsequently, 250 μl of DMEM with 20% FBS was added into cells, mixed gently 
with the transfection media and the cells were incubated for 16 hrs. Next, the fresh cell culture 
media substituted the transfection media and the cells were incubated for 48 hrs before X-gal 
staining was performed. 
2.13.4 Transfection of primary mice tail fibroblasts with Fugene 6 
Primary fibroblasts were seeded in a 24-well plate at a density of 5×104 cells/well. Ninety-seven 
microliters of the DMEM media was pipetted into a mirofuge tube. Three microliters of Fugene 
6 was pipetted into the DMEM media directly without allowing contact with the plastic wall of 
the tube and mixed gently. One microgram of the DNA plasmid pCMV-lacZ was added into the 
tube, mixed gently and the DNA-Fugene 6 mixture were incubated at room temperature for 30 
min. 150 μl of the DMEM media was added into the mixture, mixed gently and the total 250 μl 
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of DNA-Fugene 6 mixture was added into cells in a drop-wise manner and the cells were 
incubated for 6 hrs. Next, 250 μl of DMEM with 20% FBS was added into cells, mixed with the 
tranfection media gently and the cells were incubated for 48 hrs before X-gal staining.   
2.13.5 Transfection of primary mice tail fibroblasts with TransIT ExpressTM 
Primary fibroblasts were seeded in a 24-well plate at a density of 5×104 cells/well. Eight 
microliters of TransIT ExpressTM was diluted in 100 ul of Opti-MEM, mixed gently and 
incubated at room temperature for 15 min. One microgram of the DNA plasmid pCMV-lacZ was 
added into the mixture, pipetted gently and mixed gently. The liposome-DNA mixture was 
incubated at room temperature for 15 min. Subsequently, 150 μl of Opti-MEM was added into 
DNA-TransIT ExpressTM mixture, mixed gently, and the total of 250 μl of mixture was added 
into the cells and incubated for 1 hr. Next, 250 μl of fresh culture media was added into the 
transfection mixture and the cells were incubated for 48 hrs. Finally, X-gal staining was 
performed. 
2.13.6  Transfection of primary mice tail fibroblasts by electroporation 
Primary fibroblasts were seeded in a 6-well plate at a density of 1×106 cells/well. Before 
electroporation, the cultured fibroblasts were trypsinized and resuspended in 0.8 ml of PBS. The 
suspension was transferred into a 0.2 cm electroporation cuvett, and 5 μg of the DNA plasmid 
pCMV-lacZ was added into cells and were mixed gently by pipetting. The cells were incubated 
on ice for 10 min. Next, the cells were electroporated in GenePulser Xcell (Bio-Rad 
Laboratories, Hercules, CA) with the following condition. Pulse type: exponential decay; 
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Voltage: 160V; C: 500 μF; PC ohm: ∞. After electroporation, the cells were incubated on ice 
again for recovery for 10 min and were then seeded into a 6-well plate. The cells were incubated 
for 48 hrs before X-gal staining was performed. 
2.14 INDUCTION OF INOS EXPRESSION IN FOUNDER MICE FIBROBLASTS 
USING PSWITCH-LIPOFECTAMINE LTX TRANSFECTION 
Founder fibroblasts were seeded in 6-well plates at a density of 1×105 cells/well or 2×105 
cells/well according to the available number of cells. Each line of cells was seeded in three wells. 
One well of cells was transfected using the DNA plasmid pSwitch but not induced by 
mifepristone. The other two wells of cells were transfected using the DNA plasmid pSwitch and 
induced by mifepristone. pSwitch (2.5 μg) was gently mixed with 500 μl of Opti-MEM. Plus 
(2.5 μl) was added, gently mixed and the mixture was incubated at room temperature for 10 min. 
Next, 6.25 μl of lipofectamine LTX was added, gently mixed and the mixture was incubated at 
room temperature for 30 min. Five hundred microliters of Opti-MEM were added into mixture, 
mixed gently, and the total 1000 μl of the DNA-liposome mixture was added into the cells and 
incubated for 6 hrs. Next, 2000 μl of DMEM medium (Dulbecco’s Modified Eagle Medium 
(high glucose, Invitrogen)) with 20% FBS was added into cells, mixed with the transfection 
medium and the cells were incubated for 24 hrs. Subsequently, the media in one well was 
replaced by 2 ml of fresh cell culture media and the media in other two wells was replaced by 2 
ml of fresh cell culture media with 10-7 M mifepristone. The cells were incubated for 48 hrs. At 
the time points of 24 and 48 hrs, nitrite levels were measured in the culture media.  
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2.15 INDUCTION OF LUCIFERASE ACTIVITY IN FIBROBLASTS BY 
COINFECTION OF ADSWITCH AND AD5XGAL4-LUC 
Wild type C3B6F1 tail fibroblasts were seeded in 6-well plates at a density of 3×105 cells/well. 
Adenoviral vectors AdSwitch and Ad5xGal4-luc were mixed with 1000 μl of Opti-MEM at a 
MOI of 500, respectively, and were used to infect cells for 18 hrs. Subsequently, the infection 
media were replaced by 2 ml of fresh culture media and the cells were allowed to recover for 24 
hrs. Next, the cells were induced by mifepristone for 24 hrs in 2 ml of fresh culture media with 
addition of 10-7M mifepristone. Subsequently, the cells were induced again for another 24 hrs in 
fresh culture media with 10-7M mifepristone. Finally, the cell lysate was harvested and protein 
concentration was determined. Luciferase activity was measured and relative luciferase activity 
was obtained. 
2.16 CONSTRUCTION OF THE DNA PLASMIDS PICAM2-SWITCH, PSMMHCS-
SWITCH AND PGENEA-INOS 
To develop vascular-specific iNOS inducible transgenic mice, we modified the GeneSwitch 
system (Invitrogen). In the DNA plasmid pSwitch, either the smooth muscle cell-specific 
promoter SMMHCS (-2305 ~ 4 bp) or the endothelial cell-specifc promoter ICAM2 (-292 ~ 44 
bp) was used to replace the universal promoter herpes simplex virus tyrosine kinase, to regulate 
the Swich expression. The constructed DNA plasmids were named as pSMMHCS-Switch and 
pICAM2-Switch. We also inserted the human iNOS gene into the response plasmid pGenev5-
His A and constructed the iNOS basal expression DNA plasmid pGeneA-iNOS. 
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To construct the DNA plasmid pSMMHCS-Swtich, the DNA plasmid pSwitch was cut 
by the restriction enzymes Mlu I and Sbf I sequentially to remove the Gal4DBD binding 
sequence and the universal promoter herpes simplex virus thyminding kinase minimal promoter, 
and then this vector fragment was dephosphated by alkine phosphatase (Roche Applied 
Sciences). To clone the rabbit SMMHCS promoter, the DNA plasmid pSMMHCS-EGFP was 
linearized by the restriction enzyme Apa I. The SMMHCS promoter was cloned from the 
linerized pSMMHCS-EGFP by PCR. The primers used for PCR were: 5’: 
AATACCTGCAGGGTCGACCTGCAGGTCAACGGATCCTT; 3’: 
AATAACGCGTGCGCGCCTCGGACGCTGCTCTTTATA. The PCR condition was: 94°C , 
15min; 94°C, 30 sec, 70°C, 30 sec, 72°C, 180 sec (35 cycles); 72°C, 10 min. The PCR product 
of the SMMHCS promoter was cut by restriction enzymes Mlu I and Sbf I sequentially. Next, the 
SMMHC promoter fragment and the vector pSwitch fragment were ligated at 16°C overnight 
and the DNA plasmid pSwitch-SMMHCS was constructed. 
The procedure to construct the DNA plasmid pSwitch-ICAM2 is similar as above. The 
ICAM2 promoter was cloned from the DNA plasmid pAdloxICAM2, which was constructed as 
described in 2.5. The primers used to clone the ICAM2 promoter were: 5’: 
AATACCTGCAGGCCATGGGATTTGGGGTTCCCCAGATCTG 3’: 
AATAACGCGTCCAAGGGCTGCCTGGAGGGAGATG. The PCR condition was: 94°C , 
15min; 94°C, 30 sec, 54°C, 30 sec, 72°C, 60 sec (35 cycles); 72°C, 10 min.   
To construct the DNA plasmid pGeneA-iNOS, the DNA plasmid pGene/V5-hisA was 
codigested by the restriction enzymes Hind III (Roche Diagnostics) and Not I at 5’ and 3’ end, 
respectively. To release the human iNOS gene from the DNA plasmid pcDNA3-iNOS, pcDNA3-
iNOS was codigested by Hind III (Roche Diagnostics) and Not I. Next, the vector pGene/V5-
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hisA fragment was ligated with the insert (human iNOS fragment) by T4 DNA ligase and the 
DNA plasmid pGeneA-iNOS was constructed.  
 
  
 
  
Figure 11 Construction of pSwitch-SMMHC, pSwitch-ICAM2, pGeneA-iNOS from pSwitch and pGene/v5-
hisA. 
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Figure 11 shows the structure of the DNA plasmids pSwitch-SMMHCS, pSwitch-ICAM2 
and pGeneA-iNOS. 
2.17 DETERMINATION OF GLOBAL INFLAMMATION IN DONOR GRAFTS 
To determine the global inflammation grade in the donor graft, the donor graft was harvested and 
cut into two to four sections from apex to base and each section was embedded in paraffin. The 
graft tissue in each paraffin block was cut at two levels, which were 40 μm apart. Altogether, 
there were 4 to 8 levels of graft sections from apex to base. At each level, the tissue section was 
stained by the H&E staining in the pathohistology lab. The staining slides were evaluated blindly 
by Dr. Eizaburo Sasatomi (U. Pittsburgh) to grade the acute rejection in the donor heart. Grading 
is according to the criteria made by the International Heart and Lung Transplantation Society 
(IHLTS) in 1990 as following:  
Grade 0: Negative for acute rejection 
Grade 1A: focal mild acute rejection 
Grade 1B: Diffuse mild acute rejection 
Grade 2: Focal moderate acute rejection 
Grade 3A: Multifocal moderate acute rejection 
Grade 3B: Diffuse moderate acute rejection 
Grade 4: Diffuse aggressive polymorphous infiltrate with necrosis. 
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2.18 DETERMINATION OF CARDIAC ALLOGRAFT ARTERIOSCLEROSIS IN 
DONOR GRAFTS 
Cardiac allograft arteriosclerosis was determined by measuring the percentage of vessel 
occlusion in the donor grafts. As described in 2.17, after harvested, the donor grafts were divided 
into 2 to 4 sections and each section was embedded in paraffin. Graft tissue in each paraffin 
block was cut at two levels, which were 40 μm away. Altogether, there were 4 to 8 levels of graft 
section from apex to base. At each level, the tissue section was stained by verhoeff's Van Geison 
(vVG) staining. Pictures were taken for arteries in the tissue section using a reflected light 
differential interference contrast microscope (Olympus Provis AX70, Tokyo, Japan). Vessel 
occlusion was measured using Metamorph software. Figure 10 represents a vVG staining section 
of a human coronay artery with severe cardiac allograft arteriosclerosis (183). Metamorph 
estimated the areas of the internal elastic lamina and lumen. The percentage of the vessel 
occlusion was calculated using the following formula: 
 
 57 
 
Figure 12 Determination of the percentage of vessel occlusion. 
 
 To get the mean and stardard deviation of vessel occlusion in the donor graft, we 
established our criteria to count vessels in the tissue section: 1. The vessel diameter ≥30µm; 2. 
The vessel should be an artery, not vein. 3. The vessel should have an identifiable internal elastic 
lamina; 4. The vessel should be represented cross section, but not the mix of cross and tangential 
section. 
We also employeed the grading system described by Dr. Anthony J. Demetris to grade 
cardiac allograft arteriosclerosis (175). The grade criteria are as following: 
Grade 0: no occlusion 
Grade 1: Vessel occlusion >0 and ≤10%; 
Grade 2: Vessel occlusion >10% and ≤ 25%. 
Grade 3: Vessel occlusion >25% and ≤ 50%. 
Grade 4: Vessel occlusion >50% and ≤ 75%. 
Internal elastic lamina (IEL) External elastic lamina (EEL)
Intimal hyperplasia 
Vessel occlusion %  =  
Lumen
Area of LEL-Area of Lumen (Area of IH) × (100%)Area of IEL 
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Grade 5: Vessel occlusion > 75%. 
2.19 SEQUENTIAL INJECTION OF LIPOSOME-ADCMV-LACZ OR ADCMV-EGFP 
Liposomes containing DOTAP and cholesterol in a 1:1 molar ratio were prepared as follows. 
The lipid mixture in chloroform was dried under a stream of nitrogen as a thin layer in a 100-ml 
round-bottomed flask, which was further desiccated under vacuum for 2 h. The lipid film was 
hydrated in 5% dextrose in water to give a final concentration of 10 mg DOTAP/ml. Preparation 
of small unilamellar vesicles by extrusion was performed as follows. The lipid solution was 
briefly sonicated, followed by incubation at 50°C for 10 min, and then sequentially extruded 
through polycarbonate membranes with the following pore sizes: 1.0, 0.6 and 0.2 μm. The size 
of liposomes was around 150 nm as measured by dynamic laser scattering using a Coulter N4SD 
particle sizer (Hialeah, FL, USA). 
The amount of DOTAP:cholesterol liposomes and adenoviral vector per mouse was 900 
nmol and 1011 viral particles, respectively. All of the dilutions were made in saline. Four mice 
received an injection of 150 μl of liposome through the tail vein. Five minutes later, 150 μl of 
adenoviral vector AdCMV-lacZ was injected via the tail vein again. In another group, four mice 
received 150 μl of liposome and then 150 μl of adenoviral vector AdCMV-EGFP. Control mice 
only received AdCMV-lacZ or AdCMV-EGFP (n=4). 
Three days later, the mice were sacrificed. Heart and lung were harvested and transgene 
expression was determined. 
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3.0  RESULTS: DEVELOPMENT OF GENE DELIVERY SYSTEM FOR INOS 
SPECIFIC EXPRESSION 
3.1 DEVELOPMENT OF ENDOTHELIAL-SPECIFIC ADENOVIRAL VECTOR 
 
NO has been shown to play an inhibitory role on the development of cardiac allograft 
arteriosclerosis. NO inhibits intimal hyperplasia by suppressing smooth muscle cell proliferation 
and migration, preventing leukocyte and platelet adhesion to endothelium & platelet aggregation, 
promoting endothelial cell proliferation and blocking endothelial cell apoptosis. NO donors, 
arginine or arginine polymer, suppressed intimal hyperplasia in the cardiac allografts even 90 
days after transplantation (97, 98). Despite these promising results, our preliminary data showed 
that iNOS expression mediated by adenoviral vector with the CMV promoter lacked tissue-
specific targeting. Consequently, the induction of iNOS in cardiomyocytes suppressed cardiac 
contractility, as supported by our preliminary data and by many other studies (111-115, 166, 
236). Furthermore, the induction of iNOS in cardiomyocytes led to apoptosis and exacerbated 
acute rejection after transplantation (117-119, 126). 
Based on these studies, we want to take an advantage of the inhibitory effect of iNOS on 
cardiac allograft arteriosclerosis while avoiding its detrimental role on cardiac function by 
vascular-specific expression. In this chapter, we describe the establishment of two vascular-
specific gene delivery systems. One is the adenoviral vector system with vascular-specific 
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promoter to regulate iNOS specific expression. Another is the development of vascular-specific 
iNOS inducible transgenic mice in which vascular-specfic promoter was employed. Our goal is 
to specifically target cardiac endothelial cells or smooth muscle cells.  Therefore, we first 
identified a smooth muscle- or endothelial-specific promoter that can target cardiac vasculature 
well. 
3.1.1 To identify smooth muscle- or endothelial cell-specific promoters in vitro 
In the past decade, several endothelial- or smooth muscle cell-specific promoters have been 
identified. The endothelial cell-specific promoters include the murine TieSE (promoter + 1.6kb 
enhancer) (128), the murine Tie2LE (promoter + 10kb enhancer) (128), the human ICAM2 
promoter (-292 ~ +44 bp) (129), the human vWF promoter (promoter + enhancer, -487 ~ +246 
bp) (130), the human Flt-1 promoter (promoter, -748 ~ +284 bp) (137), the murine vascular 
endothelial cadherin promoter (-2486 ~ +24 bp) (131), the murine preproendothelin-1 promoter 
with small enhancer (5.9kb 5’ flank region + first exon + first intron) (132), and the murine 
preproendothelin-1 promoter with large enhancer (9.2kb 5’flank region + first exon + first 
intron) (133). The smooth muscle cell-specific promoters include the rat SMMHCL promoter 
(promoter + large enhancer, -4229 ~ +11600 bp) (134), the rabbit SMMHCS promoter (promoter 
+ enhancer, -2305 ~ -4 bp) (135) and the murine smooth muscle 22α promoter (SM22α, -441 ~ 
+41 bp) (136). 
Though reports have suggested that the above promoters are capable of directing 
vascular-specific gene expression, conflicting results have also been reported. For example, the 
ICAM2 promoter was reported in several papers to drive endothelial-specific expression in 
transgenic mice (129, 161-165). However, Stuart et al. showed that this promoter also led to 
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leaky expression in human primary vascular smooth muscle cells, human primary foreskin 
fibroblasts, HeLa cells, and HepG2 cells when these cells were infected by an adenoviral vector 
driving the expression of lacZ in vitro (138). Moreover, these nominal endothelial- or smooth 
muscle cell-specific promoters were identified by different research groups, and direct 
comparison of these promoters’ activity and specificity remains to be investigated. In our search 
for an effective endothelial- or smooth muscle cell-specific promoter for vascular-specific 
targeting, we tested five endothelial cell-specific promoters and two smooth muscle cell-specific 
promoters in vitro. The five endothelial cell-specific promoters include the murine TieSE 
promoter (128), the murine Tie2LE promoter (128), the human ICAM2 promoter (-292 ~ +44 
bp) (129), the human vWF promoter (-487 ~ +246 bp) (130), and the human Flt-1 promoter (-
748 ~ +284 bp) (137). The smooth muscle cell-specific promoters include the rat SMMHCL 
promoter (-4229 ~ +11600 bp) (134), and the rabbit SMMHCS promoter (-2305 ~ -4 bp) (135). 
3.1.1.1 Characterization of the Tie2SE, Tie2LE, ICAM2, and Flt-1 promoters in endothelial 
cells in vitro 
To compare the activity and specificity of three endothelial cell-specific promoters 
Tie2SE, ICAM2, and vWF, the DNA plasmids pTie2SE-FretMT, pICAM2-FretMT, and pvWF-
FretMT were used to transfect endothelial cells (BAEC) and non-endothelial cells (primary rat 
smooth muscle cells and HEK293 cells). The DNA plasmid pCMV-FretMT was used as a 
positive control for the FretMT expression due to the promiscuous nature of the CMV promoter, 
and pCMV-lacZ served as a negative control. The expression of the reporter gene was 
represented by the percentage of cells exhibiting green fluorescence. Each transfection was 
performed in three wells of a 12-well plate. This experiment was repeated three times. The data 
shown represent the average from one experiment. 
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Table 2 Determination of endothelial cell-specific promoter. 
 Rat SMC BAEC HEK293 Rat hepatocytes 
pTie2-FretMT 0 3% 0.5% / 
pICAM2-FretMT 0.4% 5% 5% / 
pvWF-FretMT 0 0.5% 0.5% / 
pCMV-FretMT 10% 15% 60% / 
pTie2LE-lacZ / 7% 0.3% 0.1% 
pCMV-lacZ / 30% 50% 10% 
 
As shown in Table 2 and Figure 13, the Tie2SE promoter exhibited good gene expression 
and endothelial-specificity. The ICAM2 promoter also exhibited good gene expression and 
specificity in endothelial cells, although it also expressed some in HEK293 cells (approximately 
5% of the cells exhibited green fluorescence). Compared to the CMV promoter which was 
associated with green fluorescence in 60% of HEK293 cells, the expression directed by the 
ICAM2 promoter was minor. The vWF promoter did not drive appreciable gene expression in 
any of the cells examined. The negative control pCMV-lacZ did not exhibit any green 
fluorescence. 
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Figure 13 Green fluorescence of BAEC, rat smooth muscle cells, and HEK293 cells transfected by pICAM2-
FretMT, pTie2SE-FretMT, pvWF-FretMT, pCMV-FretMT, or pCMV-lacZ. 
pICAM2-
FretMT 
pTie2SE-
FretMT 
pvWF-
FretMT 
pCMV-
FretMT 
pCMV-
lacZ 
 64 
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Figure 14 X-gal staining of BAEC, rat hepatocytes, and HEK293 cells transfected by pTie2LE-lacZ, pCMV-
lacZ, or pCMV-FretMT. 
 
To test the Tie2LE promoter, pTie2LE-lacZ, pCMV-lacZ and pCMV-FretMT were used 
to transfect BAEC, rat hepatocytes, and HEK293 cells. pCMV-lacZ and pCMV-FretMT served 
as positive and negative controls, respectively, for β-galactosidase expression. After transfection, 
X-gal staining was performed and the percentage of blue-stained cells was calculated. Each 
transfection was performed in three wells of a 12-well plate. This experiment was repeated three 
times. Table 2 and Figure 14 show that the Tie2LE promoter demonstrated good activity in 
pCMV-
lacZ 
pTie2LE-
lacZ 
pCMV-
FretMT 
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BAEC while exhibiting very low activity in rat hepatocytes and HEK293 cells.  The negative 
control pCMV-FretMT did not exhibit any positive X-gal staining. 
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Figure 15 Relative luciferase activity of BAEC, rat smooth muscle cells, and HEK293 cells transfected by 
pFlt-1-luc, pRSV-luc and pCMV-EGFP. 
 
To address the specificity and activity of the Flt-1 promoter, the DNA plasmids pFlt-1-
luc, pRSV-luc, and pCMV-EGFP were transfected into BAEC, rat hepatocytes, and rat smooth 
muscle cells. pRSV-luc and pCMV-EGFP served as positive and negative controls, respectively. 
Forty-eight hours after transfection, the cells were lysed and the relative luciferase activity was 
compared.  Each transfection was performed in three wells of a 12-well plate, which generates 
the mean and standard deviation of the relative luciferase activity. This experiment was repeated 
three times and the data shown in Figure 15 represents the result from one experiment. As shown 
in Figure 15, the Flt-1 promoter demonstrated good activity in BAEC, although it also exhibited 
some expression in rat hepatocytes. 
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3.1.1.2 Lack of SMC-specific activity of both the SMMHCL (-4229~ +11600bp) and the 
SMMHCS (-2305~ 4pb) promoters in vitro 
We also tested two smooth muscle cell-specific promoters in vitro: rat SMMHCL (-4229 
~ +11600 bp) and rabbit SMMHCS (-2305~-4 bp). We compared their activity and specificity in 
both primary rat smooth muscle cells and other cell types (BAEC, rat hepatocytes, and HEK293 
cells). The DNA plasmids pSMMHCL-luc, pSMMHCS-EGFP, pRSV-luc, and pCMV-EGFP 
were used to transfect cells. As shown in Figure 16 and Figure 17, the SMMHCL promoter was 
not effective at driving gene expression in either cultured smooth muscle cells or HEK293 cells. 
In contrast, the SMMHCL promoter drove some gene expression in BAEC and hepatocytes. The 
SMMHCS promoter did not lead to appreciable expression in either cultured smooth muscle 
cells (Figure 18), BAEC or HEK293 cells (data not shown). 
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Figure 16 Relative luciferase activity when BAEC, hepatocytes and SMC cells were transfected by 
pSMMHCL-luc, pRSV-luc, pCMC-beta-gal and pCMV-EGFP. 
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Figure 17 Relative luciferase activity when HEK293 cells were transfected by pSMMHCL-luc, pFlt-1-luc, 
pRSV-luc, pCMC-lacZ and pCMV-EGFP. 
 
  pSMMHCS-EGFP                 pCMV-EGFP                       pCMV-lacZ 
                         
Figure 18 Green Fluorescence when SMC was tranfected by pSMMHCS-EGFP, pCMV-EGFP and pCMV-
lacZ. 
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3.1.1.3 Conclusion 
 
From the above study, we concluded that the Tie2SE, Tie2LE, ICAM2 and Flt-1 promoters 
demonstrated good endothelial activity and specificity in vitro. The vWF promoter did not 
exhibit endothelial-specific activity in vitro. The SMMHCS and SMMHCL promoters did not 
exhibit smooth muscle cell-specific activity in vitro. 
3.1.2 Endothelial-specific activity of the Flt-1 and ICAM2 promoters in vitro using AdFlt-
1-lacZ and AdICAM2-lacZ to infect cells. 
To further compare the endothelial activity and specificity of the Flt-1, ICAM2 and vWF 
promoters, we infected BAEC, rat SMC and hepatocytes in vitro at a MOI of 100 using 
adenovirus AdFlt-1-lacZ, AdICAM2-lacZ and AdvWF-lacZ. AdCMV-lacZ and AdCMV-EGFP 
were used as positive and negative controls, respectively.  As shown in Table 3, both the Flt-1 
and ICAM2 promoters exhibited good endothelial activity in BAEC while both of the promoters 
exhibited some activity in SMC and relatively high activity in hepatocytes. The vWF promoter 
did not exhibit any activity in any cell types. 
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Table 3 Endothelial activity of the Flt-1, ICAM2 and vWF promoters in SMC, BAEC and hepatocytes using 
adenovirus infection. 
 SMC BAEC Hepatocytes 
AdFlt-1-lacZ 5% 15% 30% 
AdICAM2-lacZ 20% 25% 70% 
AdvWF-lacZ 0 0 0 
AdCMV-lacZ 30% 70% 95% 
AdCVM-EGFP 0 0 0 
 
3.1.3 Endothelial-specific activity of the Flt-1 and ICAM2 promoters in ex vivo 
transduced aorta 
To further compare the specificity and activity of endothelial cell-specific promoters in intact 
tissues, rat aortae, cardiac muscle, and skeletal muscle were transduced using the adenoviral 
vectors AdFlt-1-lacZ, AdICAM2-lacZ, or AdvWF-lacZ at a dose of 2 x 109 PFU. In these 
studies, AdCMV-lacZ and AdCMV-EGFP served as positive and negative controls, respectively, 
for β-galactosidase expression. This experiment was repeated five times. 
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The upper left panel is composed of two pictures. 
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Figure 19 X-gal staining of rat aorta, cardiac muscle, and skeletal muscle transduced by AdICAM2-lacZ, 
AdFlt-1-lacZ, AdvWF-lacZ, AdCMV-lacZ, or AdCMV-EGFP. 
 
As shown in Figure 19, approximately 10% of the endothelial cells and 8% of the 
adventitial cells exhibited X-gal staining in the AdFlt-1-lacZ-transduced aorta, but no staining 
was observed in smooth muscle cells. Transduction of cardiac muscle and skeletal muscle 
resulted in a low number of X-gal-positive muscle cells in both tissues. In the AdICAM2-lacZ 
transduced tissues, 7% of the endothelial cells and 2% of the adventitial cells exhibited X-gal 
staining, while few other cell types exhibited positive staining. In the AdvWF-lacZ-transduced 
tissues, few cells exhibited X-gal staining. The AdCMV-EGFP-transduced tissue was negative 
for lacZ expression. The vWF promoter did not lead to X-gal staining in any of the tissues 
examined. The negative control AdCMV-EGFP did not exhibit any positive X-gal staining. 
AdCMV-
lacZ 
AdCMV-
EGFP 
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3.1.4 Construction of adenovirus vectors AdFlt-1-iNOS, AdICAM2-iNOS and AdTie2SE-
iNOS and test the endothelial specificity of the Flt-1, ICAM2, and Tie2SE promoters in 
vitro 
Based on the in vitro and ex vivo test results, we can determine that the Flt-1, ICAM2, Tie2SE 
and Tie2LE promoters were possible candidates for endothelial-specific targeting. To achieve 
endothelial-specific expression of iNOS, we constructed three adenoviral vectors AdFlt-1-iNOS, 
AdICAM2-iNOS and AdTie2-iNOS and tested their specificity in vitro. These adenovirus are 
E1, E3 deleted adenovirus and can accommondate up to 7~8 kb of foreign genes. The Tie2LE 
promoter (>10kb) is too large to be inserted into the adenoviral vector. 
The construction of the adenoviral vectors AdFlt-1-iNOS, AdICAM2-iNOS and 
AdTie2SE-iNOS was described in 2.5. 
Next, we wanted to determine if the Flt-1, ICAM2 and Tie2SE promoters lead to 
endothelial-specific expression of iNOS in vitro using AdFlt-1-iNOS, AdICAM2-iNOS and 
AdTie2SE-iNOS. BAEC and rat hepatocytes were infected by AdFlt-1-iNOS, AdICAM2-iNOS 
and AdTie2SE-iNOS with a MOI of 400 for 2 hours, then the infection media was replaced by 
the cell culture media. Twenty-four and 48 hours after infection, the culture media was collected 
and the nitrite level in the media was measured using the Greiss assay. Forty-eight hours after 
infection, RNA was extracted from cells. Cell lysates were harvested. RT-PCR and western blot 
were performed to determine iNOS expression. 
As shown in Figure 20 and Figure 21, western blot results showed that the Flt-1, ICAM2 
and Tie2SE promoters drove iNOS protein expression in BAEC, but not in hepatocytes. Figure 
22 showed that the ICAM2 promoter led to significant increase of the nitrite level in the culture 
media at 48 hours after BAEC were infected by AdICAM2-iNOS, but no increase in that of 
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hepatocytes. The Flt-1 promoter did not lead to significant increase of the nitrite level in either 
BAEC or hepatocytes (Figure 23), and neither did the Tie2SE promoter (data not shown). The 
Flt-1 and Tie2SE promoters drove iNOS protein expression in BAEC that was detected by 
western blot, but the nitrite level could not be detected by Greiss assay. This controversy may be 
because that Greiss assay is less sensitive than western blot to detect iNOS expression. The RT-
PCR results were shown in Figure 24.  In AdFlt-1-iNOS and AdIACM2-iNOS infected rat 
hepatocytes, both the Flt-1 and ICAM2 promoter led the human iNOS gene to be transcribed. 
However, the iNOS protein expression could not be detected in the cells as shown in Figure 21. 
We have observed this when we used the DNA plasmid pTie2SE-iNOS to transfect hepatocytes, 
the human iNOS gene was transcribed in the hepatocytes (Figure 25). However, the iNOS 
protein was not detectable in hepatocytes by western blot (Figure 26). 
 
 
           
    
            +          AdFlt-1  AdICAM2 AdTie2SE AdCMV        AdCMV 
          Control   -iNOS       -iNOS      -iNOS      -iNOS           -lacZ 
Figure 20 Western blot results show that the human iNOS protein was expressed in BAEC when BAEC were 
infected by AdFlt1-iNOS and AdICAM2-iNOS (400 MOI). 
AdCMV-iNOS served as a positive control; AdCMV-lacZ was a negative control. From left to right, 1: hiNOS 
positive control; 2,3: AdFlt-1-iNOS; 4,5, 6: AdICAM2-iNOS; 7, AdCMV-iNOS; 8,9, 10: AdCMV-lacZ. 
 
actin 
  hiNOS   
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        AdFlt-1   AdICAM2 AdTie2SE        AdCMV                AdCMV        + control 
           -iNOS          -iNOS     -iNOS          -iNOS                      -lacZ 
Figure 21 Western blot results show that the human iNOS protein was not detectable in rat hepatocytes when 
they were infected by AdFlt1-iNOS and AdICAM2-iNOS (400 MOI). 
From left to right, 1, 2, 3: AdFlt-1-iNOS;  4, 5, 6: AdICAM2-iNOS; 7, 8.9: AdCMV-iNOS; 10, 11, 12: AdCMV-
lacZ; 13: hiNOS positive control. 
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Figure 22 Nitrite levels in the cell culture meida when BAEC were infected by AdFlt-1-iNOS, AdICAM2-
iNOS, AdCMV-iNOS and AdCMV-lacZ. 
hiNOS 
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Figure 23 Nitrite levels in the cell culture meida when rat hepatocytes were infected by AdFlt-1-iNOS, 
AdICAM2-iNOS, AdCMV-iNOS and AdCMV-lacZ. 
 
 
           
 
Figure 24 RT-PCR results show that human iNOS was transcribed in rat hepatocytes when they were 
infected by AdFlt-1-iNOS and AdICAM-iNOS (400MOI). 
hiNOS 
β-actin  
AdFlt-1-       AdICAM2-   AdCMV-         No          AdCMV
  iNOS              iNOS             lacZ         infection       iNOS 
 76 
 AdCMV-iNOS served as a positive control; AdCMV-lacZ and no infection were negative controls. From left to 
right, 1, 2,3: AdFlt-1-iNOS;  4,5, 6: AdICAM2-iNOS; 7, 8.9: AdCMV-lacZ; 10, 11, 12: AdCMV-lacZ; 13, 14, 15: 
AdCMV-iNOS 
 
Figure 25 RT-PCR results show that human iNOS was transcribed in rat hepatocytes when they were 
transfected by pTieSE-iNOS. 
pCMV-iNOS serves as a positive control; pCMV-EGFP and no infection were negative controls. From left to right, 
1, 2,3: No infection;  4,5, 6: pCMV-EGFP; 7, 8.9: pCMV-iNOS; 10, 11, 12: pTieSE-iNOS. 
 
 
 
   No transfection pCMV-EGFP  pCMV-iNOS    pTie2SE-iNOS  
Figure 26 Western blot results show that the human iNOS protein was not detectable when rat hepatocytes 
were transfected by pTieSE-iNOS. 
pCMV-iNOS served as a positive control. pCMV-EGFP and no transfection were negative controls. From left to 
right, 1, 2,3: No infection;  4,5, 6: pCMV-EGFP; 7, 8.9: pCMV-iNOS; 10, 11, 12: pTieSE-iNOS. 
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These data demonstrated that the Flt-1, ICAM2 and Tie2SE promoters led to endothelial- 
specific expression of the human iNOS in BAEC. 
3.1.5 Endothelial-specific activity of the ICAM2 promoter in the endothelium of donor 
heart 
Our goal is to identify an endothelial-specific promoter that will lead to iNOS specific expression 
in cardiac endothelium. We next determined if the Flt-1 and ICAM2 promoters drove gene 
expression in cardiac endothelium in vivo using AdFlt-1-lacZ and AdICAM2-lacZ. 
To determine if the Flt-1 and ICAM2 promoters drove gene expression in cardiac 
endothelium in vivo, we employed a rat syngeneic heart transplantation model, in which we 
transduced donor hearts ex vivo using the adenoviral vector AdFlt-1-lacZ or AdICAM2-lacZ at a 
dose of 1010 PFU prior to transplantation. AdCMV-lacZ and AdCMV-EGFP were used as 
positive and negative controls, respectively. We adopted single injection of adenoviral vector 
into donor heart for transduction as described in 2.1.2. Three days later, the donor heart was 
harvested and the expression of LacZ was determined by X-gal staining. As shown in Figure 27, 
good lacZ expression was observed in the endothelial cells of the coronary arteries and veins in 4 
of 22 donor grafts that were transduced with AdICAM2-lacZ. In the 4 positive hearts, 22.2%, 
33.3%, 50.9% and 56.7% of coronary vessels, respectively, exhibited positive X-gal staining, 
and the average positive staining spots per vessel is 0.96, 1.94, 1.53, 5.29, respectively. A small 
percentage of cardiomyocytes also showed positive staining (Figure 27). In other 18 AdICAM2-
lacZ transduced grafts, <5% of the vessels were transduced and <0.2 staining spots were 
observed in each vessel. The Flt-1 promoter directed positive staining in a low number of 
endothelial cells (<5% of coronary vessels exhibited positive staining and <0.1 staining spots 
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were observed in each vessel) and a small percentage of cardiomyocytes. The CMV promoter 
drove extensive lacZ expression in cardiomyocytes while scattered and varied gene expression in 
endothelial cells. In one donor graft, 24.56% of coronary vessels exhibited positive staining and 
0.474 staining spots was observed in each vessel. In another 5 grafts, <5% of the vessels were 
transduced and <0.16 staining spots was observed in each vessel. The negative control AdCMV-
EGFP did not lead to positive staining in either endothelial cells or cardiomyocytes (data not 
shown). 
 
   AdICAM2-lacZ, 20X AdICAM2-lacZ, 40X 
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Figure 27 X-gal staining of donor heart that was transduced by AdFlt-1-lacZ, AdICAM2-lacZ and AdCMV-
lacZ ex vivo. 
Pictures were taken using a reflected light differential interference contrast microscope (Olympus Provis AX70, 
Tokyo, Japan). Magnification of the tissue sections was desribed in the picture. 
AdCMV-lacZ, 20X AdCMV-lacZ, 20X 
AdFlt-1-lacZ, 40X AdFlt-1-lacZ, 20X 
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3.1.6 Conclusion 
The ICAM2, Flt-1, Tie2SE (with 1.6kb enhancer), and Tie2LE (with 10 kb enhancer) promoters 
demonstrated good specificity and activity in endothelial cells. These promoters may hold 
promise for endothelial-specific targeting in vascular gene therapy applications. The Tie2LE 
promoter exhibited better endothelial activity than the Tie2SE promoter. The Flt-1, ICAM2 and 
Tie2SE promoters not only drove the lacZ gene specifically expressed in endothelial cells, but 
demonstrated good endothelial-specificity when they directed the iNOS expression. The Flt-1 
and ICAM2 promoter also exhibited good endothelial-specificity when they were tested in intact 
aorta, cardiac muscle and skeletal muscle. The ICAM2 promoter drove good lacZ gene 
expression in endothelium of the donor grafts although the transduction results varied a lot. The 
ICAM2 promoter may serve a candidate for cardiac endothelium-specific targeting. Due to the 
diversity of vasculature in different organs and tissues, additional ex vivo and in vivo tests are 
needed to determine the optimal promoters for specific applications. The human vWF, rat 
SMMHCL (-4229 ~ +11600 bp), and rabbit SMMHCS (-2305~-4 bp) promoters did not 
demonstrate vascular-specificity in this study, though additional studies may unmask specific 
applications for these promoters. 
We have successfully constructed three adenoviral vectors with endothelial-specific 
promoters to drive the human iNOS expression: AdFlt-1-iNOS, AdICAM2-iNOS and 
AdTie2SE-iNOS. The three adenoviral vectors exhibited endothelial-specific activity in vitro. 
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3.1.7 Discusion 
We compared five nominal endothelial cell-specific promoters and two putative smooth muscle 
cell-specific promoters in vitro. The activity and cell-type specificity of the Tie2LE, Tie2SE, 
ICAM2, Flt-1, and vWF promoters were tested in BAEC, rat smooth muscle cells, rat 
hepatocytes and HEK293 cells using DNA plasmid transfection. Moreover, the latter three 
promoters were also compared in intact tissues including rat aortas, cardiac muscle, and skeletal 
muscle using adenoviral transduction. We conclude that both the ICAM2 and Flt-1 promoters 
demonstrated good endothelial activity and specificity. However, the ICAM2 promoter drove a 
low degree of reporter gene expression in HEK293 cells and the Flt-1 promoter directed some 
expression in rat hepatocytes. Stuart et al. (138) and Renolds et al. (139) have also reported 
endothelial-specific activity of the Flt-1 promoter both in vitro and in vivo. The endothelial-
specificity of the ICAM2 promoter has been demonstrated in several transgenic mice lines (128, 
161-165), and our results are consistent with those findings. Stuart et al. reported that the ICAM2 
promoter drove gene expression in several non-endothelial cell lines (human foreskin fibroblasts, 
human vascular smooth muscle cells, HepG2 cells, and Hela cells) when using the adenoviral 
vector AdICAM2-lacZ. We used AdFlt-1-lacZ and AdICAM2-lacZ to infect rat hepatocytes, 
smooth muscle cells and HEK293 cells and also found some non-specific expression in these 
cells (Table 3). The difference between the cell infection data and aorta transduction data may 
pertain to the difference between cells and tissues. Oh et al. demonstrated different expression of 
endogenous proteins between cultured lung endothelial cells and lung endothelium (167). This 
difference between cells and intact tissue may explain different transgene expression pattern 
between cells and tissues after gene delivery. Moreover, we constructed AdFlt-1-iNOS, 
AdICAM2-iNOS and AdTie2SE-iNOS and used the three adenoviral vectors to infect BAEC and 
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hepatocytes. All of the promoters led to iNOS protein expression in BAEC, but not in 
hepatocytes. These data further confirmed the endothelial-specificity of the Flt-1, ICAM2 and 
Tie2SE promoters. We observed that AdFlt-1-iNOS and AdICAM2-iNOS did not lead to iNOS 
protein expression in hepatocytes while AdFlt-1-lacZ and AdICAM2-lacZ drove lacZ expression 
in hepatocytes (Table 3). The difference could be due to the fact that AdFlt-1-iNOS and 
AdICAM2-iNOS are constructed in E1, E3 deleted adenovirus while AdFlt-1-lacZ and 
AdICAM2-lacZ are in E1 deleted adenoviral backbone. The adenoviral E3 gene may affect the 
activity of the Flt-1 and ICAM2 promoter. We also observed that the Flt-1, ICAM2 and Tie2SE 
promoter led the iNOS gene to be transcribed in rat hepatocytes, but iNOS protein was not 
translated. The reason for this result remains to be elucidated. 
We also found that the vWF promoter was inactive in both cells and tissues. These 
findings are consistent with those of Stuart et al. (138), who showed that the vWF promoter was 
inactive in primary human endothelial cells, human vascular smooth muscle cells, human 
fibroblasts, HepG2 cells, and Hela cells. However, the vWF promoter has been reported to 
actively drive lacZ or amyloid-β gene expression in brain vascular endothelial cells of transgenic 
mice (130, 168). Takashi et al. also reported that this promoter directed specific β-galactosidase 
expression in endothelial cells of brain, heart, and skeletal muscle of transgenic mice, but not in 
other tissues (169). Whether this promoter is only active in endothelial cells from specific 
tissues--for example, brain, heart or skeletal muscles--remains to be determined. Takashi et al. 
suggested that the Flt-1 and vWF promoters are regulated by distinct transcriptional mechanisms, 
and this may explain our findings of different gene expression directed by the two promoters. 
This controversy also highlights the different expression patterns observed in vitro and in vivo. 
The Tie2SE and Tie2LE promoters also demonstrated good endothelial activity and specificity 
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when tested in cells. Because of their large sizes, we could not insert these promoters into 
adenoviral vectors to test their specificity in intact tissues. 
To further determine if the Flt-1 and ICAM2 promoters would lead to good gene 
expression in cardiac endothelium in vivo, we tested the two promoters in a heterotopic heart 
transplantation model by ex vivo transduction of the donor heart using adenoviral vectors. We 
employed single injection of the adenoviral vector into donor heart and incubated the adenoviral 
vector in the heart since this resulted in better transduction efficiency in endothelial cells than 
that of recirculation of the adenoviral vector in the donor heart. For unknown reasons, the 
AdICAM2-lacZ transduction in endothelium of the donor grafts varied extensively. In four 
grafts, the ICAM2 promoter led to good gene expression in endothelial cells of the coronary 
arteries and veins, as along with low expression in cardiomyocytes. These results are consistent 
with those of others (161, 163, 165), who showed that the ICAM2 promoter directed good and 
specific lacZ or CD46 gene expression in cardiac endothelium of transgenic mice. However, in 
another 18 grafts, only a low number of endothelial cells exhibited positive staining. The Flt-1 
promoter directed lacZ expression in only a low number of endothelial cells and a small 
percentage of cardiomyocytes. The CMV promoter drove low gene expression in endothelial 
cells while dramatic expression was observed in cardiomyocytes. This finding is consistent with 
previous reports showing that adenoviral gene expression driven by the CMV promoter 
transduced endothelial cells poorly in the donor heart (170-172). This finding also raises the 
possibility that our variable AdICAM2-lacZ transduction results may be due to the poor 
adenoviral transduction efficiency in vascular cells in vivo. This hypothesis awaits further testing 
using more efficient gene delivery vectors. Our data also indicate that the ICAM2 promoter may 
serve a candidate for cardiac endothelium-specific targeting. Because the great variety of 
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adenoviral transduction results, we did not use AdFlt-1-iNOS and AdICAM2-iNOS for further in 
vivo test. 
In addition to the endothelial-specific promoters, we also tested two putative smooth 
muscle cell-specific promoters: SMMHCL and SMMHCS. These two promoters were tested in 
rat smooth muscle cells, BAEC, rat hepatocytes, and HEK293 cells. Neither of these promoters 
drove adequate gene expression in cultured smooth muscle cells. One possible explanation for 
these findings is that the transfection efficiency in cultured smooth muscle cells is very low when 
using DNA plasmids. This hypothesis awaits further testing using more efficient transduction 
vectors. 
Moreover, we have sussessfully developed three endothelial cell-specific adenoviral 
vectors: AdFlt-1-iNOS, AdICAM2-iNOS and AdTie2SE-iNOS. All of the three adenoviral 
vectors exhibited endothelial-specific activity in vitro. The three adenoviral vectors drove iNOS 
protein expression in BAEC, but not in hepatocytes.  Our original plan is to use the three 
vascular-specific adenoviral vectors to infect donor heart and test our hypothesis that endothelial-
specific expression of iNOS inhibits cardiac allograft arteriosclerosis in a heart transplantation 
model. According to the data in 3.1.5, since adenoviral transduction resulted in greatly variable 
results, we did not use the three vascular-specfic adenoviral vectors for in vivo test. 
3.1.8 Liposome-AdCMV-EGFP or AdCMV-lacZ sequential injection did not lead to 
endothelial-specific gene expression in the heart 
Another strategy to enhance endothelial delivery is to utilize liposomes to promote endothelial 
uptake of adenoviral vector. When a positively charged liposome is mixed with a negatively 
charged DNA plasmid, the liposome neutralizes the negatively charged plasma membrane of cell 
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and facilitateas the endocytosis of DNA plasmid into the cell. Similarly, Dr. Song Li’s lab (U. 
Pittsburgh) showed that sequential injection of liposome and adenoviral vectors improved 
adenoviral infection efficiency in lung endothelial cells (237, 238). Specifically, 150 μl of 
liposome was quickly injected into mice via the tail veil. This injection developed hydrodynamic 
pressure in the inferior vena cava and drove liposomes into tissues, including the liver, lung, 
heart, and spleen. Five minutes later, 150 μl of AdCMV-EGFP was injected through the tail vein. 
This approach greatly enhanced the lacZ expression in pulmonary endothelial cells compared to 
the single AdCMV-lacZ injection alone. EGFP was mainly expressed in the capilliary 
endothelial cells (238). Ma et al. also found that coronary endothelial cells were well transduced 
(Figure 28, unpublished data). Based on their data, we tried sequential injection of liposome-
AdCMV-lacZ and liposme-AdCMV-EGFP and determined transgene expression in the heart and 
lung. 
Sequential injection of liposome-adenoviral vector was described in 2.19. Four mice were 
injected with liposome-AdCMV-EGFP and another four mice were injected with liposome-
AdCMV-lacZ. The control mice received single injection of AdCMV-lacZ or AdCMV-EGFP. 
Our results showed limited transgene expression (either EGFP or lacZ) in cardiomyoctes, 
endothelial cells or smooth muscle cells in the heart. In contrast, both EGFP and lacZ were 
expressed well in the lung, which is consistent with the Ma et al.’ result. The results are shown in 
Figure 29 and 30. The Control mice that received a single injection of AdCMV-EGFP or 
AdCMV-lacZ expressed much less transgene in the lung compared to the liposome-AdCMV-
EGFP or liposome-AdCMV-lacZ treatment (data not shown) 
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Figure 28 Sequential injection of liposome-AdCMV-EGFP led to EGFP expression in coronary endothelial 
cells. 
A, B: Blue and while fluorescence represented autofluorescence of coronary vessel. C: Green fluorescence 
represented GFP expression in Coronary vessel. D. Merged fluorescence of blue and green represented EGFP 
expression in coronary vessels. 
 
         
A C
B D
A B
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Figure 29 Sequenctial injection of liposome-AdCMV-EGFP drove EGFP expression in the lung, but not in the 
heart. 
A and B: lung; C and D: heart. 
 
 
 
 
          
C D
A B
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Figure 30 Sequential injection of liposome-AdCMV-lacZ led to lacZ expression in the lung, but not in the 
heart. 
A: lacZ was expressed well in the lung; B: lacZ was expressed in large lung vessels; C: lacZ expression was 
exhibited in a few of cardiomyocytes; D: lacZ expression was barely detectable in the heart. 
3.1.9 Discussion 
In this section, we used adenoviral transduction approaches to achieve endothelial-specific 
expression in rat or mouse heart. The adenoviral vectors with endothelial-specific promoter 
AdFlt-1-lacZ or AdICAM2-lacZ or adenoviral vector with universal promoter CMV was used 
with the aid of positively charged liposomes. However, neither approach resulted in consistent 
and good endothelial-specific expression in rodent heart. To achieve consistent and good 
vascular-specific expression, we moved to establish vascular-specific iNOS inducible transgenic 
mice.  
C D
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3.2 TO DEVELOP VASCULAR-SPECIFIC INOS INDUCIBLE TRANSGENIC MICE 
3.2.1 GeneSwitch is an optimal choice to make vascular-specific iNOS inducible 
transgenic mice 
In 3.1, we invested considerable effort to test 5 endothelial-specific promoters and 2 smooth 
muscle cell-specific promoters in vitro, ex vivo and in vivo. Our goal was to identify a good 
endothelial- or smooth muscle cell-specific promoter that leads to iNOS vascular-specific 
expression in the heart. From our studies, we found that the ICAM2 promoter was a promising 
candidate for cardiac endothelium specifical targeting. For smooth muscle cell-specific targeting, 
we could not determine the activity and specificity of the two promoters, SMMHCL and 
SMMHCS, due to the poor transfection efficiency in cultured smooth muscle cells. Franz et al. 
have reported that the SMMHCS promoter led to the expression of lacZ or luciferase gene 
specifically in smooth muscle cells of coronary arteries in both transgenic mice and rabbits 
(135). Thus, the SMMHCS promoter may be a good candidate for smooth muscle cell-specific 
targeting. Since we have no information on whether endothelial cell- or smooth muscle cell- 
specific expression of iNOS will inhibit the development of cardiac allograft arteriosclerosis, we 
decided to develop both endothelial cell- and smooth muscle cell- specific expression of iNOS in 
vasculature at the same time. Therefore, we chose the ICAM2 and SMMHCS promoter for 
endothelial- and smooth muscle cell-specific targeting, respectively. 
From 3.1.5, we know that adenoviral transduction in donor grafts results in variable gene 
expression. To achieve consistent transgene expression, we chose to develop another gene 
delivery system: vascular-specific iNOS inducible transgenic mice. Until now, iNOS transgenic 
mice have not been successfully generated because transgenic mice with constitutively expressed 
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iNOS do not survive to the adult stage (117). Inducible iNOS transgenic mice could serve as a 
better model to determine the effect and function of iNOS. The GeneSwitch system (Invitrogen), 
which exhibits mild inducible ability and strict basal expression in vitro and in vivo (146-148), 
offers an opportunity to overcome these limitations. GeneSwitch is an optimal option for our 
cardiac allograft arteriosclerosis project for the following reasons: 1. NO is an intracellular 
signaling molecule and exogenous supply of NO may change vascular tone. In both of the eNOS 
transgenic mice developed by Crom et al. (159) and Channon et al. (173), consistent expression 
of eNOS results in hypotension. Moreover, substantial expression of NO in cardiomyocytes has a 
negative effect on cardiac function (111-115, 120, 121, 166, 236). Therefore, an appropriate 
approach would be to regulate both the timing and location of iNOS expression. iNOS 
expression should be regulated strictly. Here, GeneSwitch provided a lowest basal expression. 2. 
Since iNOS activity is 103 higher than that of eNOS, high level induction of iNOS may have 
adverse effects. GeneSwitch affords mild level induction of transgene, which matches our need 
of iNOS induction. 3. The ligand mifepristone in the GeneSwitch system does not inhibit the 
development of intimal hyperplasia (152-155). 4. Mifepristone does not affect cardiac function 
(156). 5. GeneSwitch is easily modified using vascular-specific promoter. Therefore, we 
employed GeneSwitch toward the goal of developing vascular-specific iNOS inducible 
transgenic mouse in which the SMMHCS or ICAM2 promoter regulates the Switch specific 
expression. We propose to take the transgenic mice heart as donor and test our hypothesis that 
specific induction of iNOS in smooth muscle or endothelial cells will inhibit the development of 
cardiac allograft arterioscleorsis without suppressing cardiac function. 
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3.2.2 GeneSwitch regulates lacZ expression strictly in vitro 
To determine if GeneSwitch regulates transgene expression strictly, we transfected HEK293 
cells using DNA plasmid pSwitch and pGenev5His-lacZ as described in 2.11. Twenty-four and 
48 hrs after transfection, X-gal staining was performed. Blue-stained cells were counted and the 
percentage of blue cells was calculated using Metamorph software as described in 2.11. As 
shown in Figure 28 and 29, lacZ expression was tightly regulated by the ligand mifepristone. 
Without mifepristone, the basal expression of lacZ was mimimal which was represented that few 
cells showed blue staining. When cells were induced by mifepristone at doses of 10-10~10-7 M, 
lacZ expression was induced and demonstrated a dose-dependent expression pattern. At doses ≤ 
10-11M, few cells expressed lacZ. 
 
Figure 31 lacZ expression in HEK293 cells that were regulated by GeneSwitch. 
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Figure 32 X-gal staining of HEK293 cells after cells were transfected by GeneSwitch (pSwitch + pGenev5His-
lacZ) with or without mifepristone induction. 
A-F: lacZ expression was induced by 10-7 ~ 10-12 M of mifepristone.  G, H and I were used as negative controls. A: 
pSwitch + pGenev5His-lacZ + 10-7 M mifepristone; B: pSwitch + pGenev5His-lacZ +  10-8 M mifepristone; C: 
pSwitch + pGenev5His-lacZ + 10-9 M mifepristone; D: pSwitch + pGenev5His-lacZ + 10-10 M mifepristone; E: 
pSwitch + pGenev5His-lacZ + 10-11 M mifepristone; F: pSwitch + pGenev5His-lacZ + 10-12 M mifepristone; G: 
pGenev5His-lacZ; H: pSwitch + pGenev5His-lacZ; I: No transfection..          
3.2.3 GeneSwitch regulates iNOS expression tightly in vitro.  
After confirmation that GeneSwitch regulates lacZ expression tightly in vitro, we modified 
GeneSwitch and made three DNA plasmids in order to make vascular-specific iNOS inducible 
A
E F
G H I
B C
D 
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transgenic mice. The ICAM2 and SMMHCS promoters are employed to replace the universal 
promoter herpes simplex virus thymidine kinase mini-promoter to regulate the Switch 
expression. The three DNA plasmids are: pICAM2-Switch, pSMMHCS-Switch and pGeneA-
iNOS. The construction procedure is described in 2.16. 
To determine how GeneSwitch regulates iNOS expression, we transfected HEK293 cells 
using DNA plasmids pSwitch and pGeneA-iNOS. Subsequently, we induced the iNOS 
expression using a concentration gradient of mifepristone from 10-14 to 10-7M. Twenty-four, 48 
or 72 hrs later, we measured the nitrite level in the culture media by Greiss assay and detected 
iNOS expression by western blot. As shown in Figure 33 and 34, iNOS expression was well-
regulated by GeneSwitch. Without mifepristone induction, the basal level of nitrite in the culture 
media was mimimal. When cells were induced by mifepristone at doses of 10-10~10-7 M, iNOS 
expression was significantly induced, which was represented by the nitrite level in the culture 
media (Figure 33) and the protein band shown by western blot (Figure 34). At doses ≤ 10-11 M, 
iNOS expression went back the basal minimal level. From the time course of iNOS induction, 
we can see that iNOS expression was induced as early as 6 hrs after addition of mifepristone 
(Figure 35), reached the peak level at 24 hrs and maintained this peak level until 48 hrs after 
mifepristone induction (Figure 36). At 72 hrs after mifepristone induction, iNOS expression 
decreased considerably, which was demonstrated by western blot. As we know, HEK293 cells 
are rapidly proliferating cells and need to be split every two or three days. At the time point of 72 
hrs after addition of mifepristone, the cells had been seeded into the plate for at least 106 hrs and 
the cell viability decreased greatly. This loss of viability may be associated with the decrease of 
iNOS expression. 
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iNOS induction by GeneSwitch in HEK293 cells 
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Figure 33 Nitrite induction in the culture media after HEK293 cells were co-transfected by pSwitch and 
pGeneA-iNOS and induced by 10-14 ~ 10-7M of mifepristone. 
Cells that were tranfected by pGeneA-iNOS, pSwitch + pGeneA-iNOS, pSwitch + pGenev5His-lacZ + 10-8M 
mifepristone, or without transfection, were used as negative controls. 
 
 95 
 
Figure 34 iNOS induction by GeneSwitch in HEK293 cells. The human iNOS protein was induced when cells 
were co-transfected by pSwitch and pGenev5-iNOS and induced by 10-8M mifepristone for 24hrs. 
In control cells, or the cells that were co-transfected by pSwitch and pGenev5-iNOS but without mifepristone 
induction, or cells that were treated by 10-8M mifepristone only, the human iNOS protein was not detectable. 
 
 
Figure 35 Time course of nitrite induction after HEK293 cells were co-transfected by pSwitch and pGeneA-
iNOS and induced by 10-8 M mifepristone. 
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Figure 36 Western blot results showed the time course of iNOS induction after HEK293 cells were transfected 
by pSwitch and pGeneA-iNOS and induced by 10-8M mifepristone. 
At 24 hrs after mifepristone induction, iNOS expression reached the peark and this expression level was maintained 
until 48 hrs after mifepristone. At 72 hrs after mifepristone induction, iNOS was not induced but degraded. 
3.2.4 Generation of vascular-specific iNOS inducible transgenic mice 
After we confirmed that GeneSwitch regulates iNOS expression strictly in vitro, starting 
February 2006, we began a collaboration with Revivicor Inc. (Blacksburgh, VA) to make the 
vascular-specific iNOS inducible transgenic mice. Three DNA plasmids were constructed to 
make the vascular-specific iNOS inducible transgenic mice: pICAM2-Switch, pSMMHCS-
Switch and pGeneA-iNOS (Figure 11). Preparation of vascular-specific iNOS inducible mice 
requires two steps. The first step is to linearize the three DNA plasmids and microject the DNA 
fragment into oocytes to make three transgenic mice lines: TgICAM2-Switch, TgSMMHCS-
Switch and TgGeneA-iNOS. In the first two lines, the regulatory protein Switch is specifically 
expressed in smooth muscle or endothelial cells. TgGeneA-iNOS is an iNOS basal expression 
line. The second step is to cross TgICAM2-Switch or TgSMMHCS-Switch with TgGeneA-iNOS 
and get the vascular-specific iNOS inducible transgenic mice TgICAM2-Switch-iNOS and 
TgSMMHCS-Switch-iNOS. 
24hrs 48hrs 72hrs 
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Revivicor Inc. first microinjected pGeneA-iNOS DNA fragment into C3B6F1 mice 
oocytes and got 117 pups. By extracting genomic DNA from mouse tails and performing PCR, 
they identified 12 founders of TgGeneA-iNOS, in which the human iNOS gene is integrated into 
mice genome. Theoretically, in the transgenic mice line TgGeneA-iNOS, iNOS should not be 
expressed but is inducible when provided by the regulatory protein Switch and the ligand 
mifepristone. However, since the DNA fragment is randomly integrated into mice genome, iNOS 
could be inducible, constitutively expressed, or silent due to different integration sites. Therefore, 
we needed to screen in which line iNOS is inducible.  
The 12 founders of TgGeneA-iNOS mice (C3B6F1 strain) were housed in the animal 
facility of University of Virginia. Unfortunately, the importation of these mice into our 
quarantine facility was denied due to an infection in the Revivicor colony. To access the 
inducibility of iNOS, Revivicor Inc. harvested fibroblasts from tails of the 12 founders and 
shipped them to us for screening. The 12 founders are numbered as #24, 36, 43, 56, 63, 64, 88, 
100, 109, 110, 111 and 115, respectively. The cell number from each line was very limited, only 
1.2×105 to 6×105. These numbers of cells were not adequate for the Greiss assay used to measure 
nitrite levels or for western blot of iNOS protein. Therefore, these cells were cultured and 
allowed to proliferate. For the lines 24, 109 and 111, many of the cells died after seeding and the 
study could not be performed.  The remaining 9 lines were tested. 
3.2.4.1 Optimization of the transfection condition in adult C3B6F1 mice tail fibroblasts 
using liposome-DNA plasmid complex or by electroporation 
As described in 1.9.2, to determine in which line of cells iNOS was inducible, we need to 
provide cells with the regulatory protein, Switch and the ligand mifepristone. In order to provide 
cells with the Switch protein, we first transfected the cells using a DNA plasmid pSwitch-
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liposome mixture. As we know, the transfection effiency using DNA plasmids in adult mouse 
tail fibroblast is very poor. To guanrantee that there was enough Switch protein produced in cells 
to induce the iNOS expression, we compared the transfection efficiency of DNA-liposome in 
wild-type C3B6F1 mice tail fibroblasts using different transfection reagents, including 
lipofectamine LTX with Plus (Invitrogen), lipofectamine 2000 with Plus (Invitrogen), 
GenePORTER (Genelantis, San Diego, CA), TransIT express (Mirus Bio) and Fugene 6 (Roche 
Diagnostics). We also tranfected cells by electroporation. 2.12 describes how the tail fibroblasts 
from wild-type mice C3B6F1 were harvested and 2.13 describes the transfection methods. The 
DNA plasmid pCMV-lacZ was used to test the transfection efficiency. Table 4 shows the 
transfection results. 
 
Table 4 Optimization of transfection efficieny in C3B6F1 tail fibroblasts by different transfection reagents. 
Transfection 
reagents 
Lipofectamine 
LTX + Plus 
Lipofectamine 
2000 + Plus 
Gene-
PORTER
TransIT 
express 
Fugene 
6 
Electro-
poration
% of cells  with 
blue staining 
20% 5~10% 0.2% 0.2% 0.125% <0.1% 
 
Using lipofectamine LTX with Plus, 20% of tail fibroblasts were transfected and 
exhibited blue staining. Lipofectamine LTX is a new transfection reagent and transfection 
effiency of 20% in adult mouse tail fibroblasts has not been previously reported in the literature. 
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3.2.4.2 Identification of iNOS inducible transgenic mice using pSwitch-lipofectamine LTX 
transfection 
As mentioned in the introduction of 3.2.4, we had obtained 9 lines of cells from 
TgGeneA-iNOS founders for testing:  36, 43, 56, 63, 64, 88, 100, 110 and 115. We transfected 
these cells using lipofectamine LTX with Plus mixed with pSwtich and determined which line of 
cells was inducible for iNOS expression. According to the cell number, these cells were seeded 
in 6-well plates at a density of 1×105 cells/well or 2×105 cells/well. Each line of cells was seeded 
in 3 wells of a 6-well plate. One well of cells was transfected by pSwitch, but not induced by 
mifepristone as a negative control, the other two wells of cells were transfected by pSwitch and 
induced by mifepristone to determine the iNOS induction. The transfection and induction 
conditions were described in 2.14.  
The transfection results showed that none of the cell lines demonstrated production of 
nitrite (data not shown). This could be due to the possibility that the cell line is inducible but 
with only 20% transfection efficiency the cells still did not generate enough Switch protein to 
induce the iNOS expression, or it could be that these cell lines were not inducible for iNOS 
expression. To increase the transfection efficiency, we aquired an adenoviral vector that 
expresses the Switch protein. The GeneSwitch system has been placed in adenoviral vectors as 
AdSwitch and Ad5xGal4-luc in Dr. Ramesh A Bhat’s laboratory (Weyth Research). AdSwitch is 
the regulatory vector that expresses the Switch protein and Ad5xGal4-luc is the responsive 
vector that regulates the induction of luciferease gene. We obtained the adenoviral vectors 
AdSwitch and Ad5xGal4-luc from Dr. Ramesh A Bhat. We then used AdSwitch to infect 
founder tail fibroblasts, established a condition under which >95% of cells could be infected and 
determined if any of the cell line was inducible for iNOS. 
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3.2.4.3 Optimization of infection condition in adult mice tail fibroblasts using AdSwitch 
We first tried to find a condition under which >95% of the adult mouse tail fibroblasts 
were infected and produced transgene when infected by the adenoviral vector.  
We infected adult mouse tail fibroblasts from wild-type C3B6F1 mice using AdCMV-
lacZ for 6 or 18 hrs with different MOI: 100, 200, 300, 400 and 500. The cells were then 
incubated in fresh cell culture media for 48 hrs. Next, X-gal staining was performed to determine 
the infection efficiency. There was no cell toxicity observed in any of the above infection 
conditions. As shown in Table 5, when infected for 6 hrs, with the MOI of 500, 95% of the cells 
exhibited blue staining; when infected for 18 hrs, with the MOI of 300, 400 or 500, at least 95% 
of the fibroblasts exhibited blue staining. However, with different MOI and infection duration, 
the amount of lacZ produced by the cells varied, which was represented by the intensity of blue 
color. The higher MOI, the longer infection duration, the more intense the blue staining was. 
Finally, we chose the MOI of 500 and infection for 18 hrs as our infection condition. 
 
Table 5 Determine transfection efficiency in adult mouse tail fibroblasts using AdCMV-lacZ. 
 MOI 100 MOI 200 MOI 300 MOI 400 MOI 500 
% of blue cells when 
infected for 6 hrs 
50% 60% 80% 90% 95% 
% of blue cells when 
infected for 18 hrs 
80% 90% 95% >95% >95% 
 
Next, we determined if AdSwitch and Ad5xGal4-luc infection led to functional protein in 
the cells. We first determined if AdSwitch made the Switch protein. We infected wild-type 
C3B6F1 tail fibroblasts using AdSwitch at a MOI of 500 for 18 hours, and then incubated the 
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cells in fresh culture media for 48 hours. Subsequently, we harvested the cell lysate for western 
blot. The uninfected cells were used as a negative control. A stem cell line, B6G-2 (Riken 
BioResource center, Ibaraki, Japan), was also infected by AdSwitch, as a positive control, and 
non-infected cells as a negative control. A rabbit anti-Gal4 (DBD) (N-19) polyclonal antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) was used to detect the Switch protein (147). As 
shown in Figure 37, AdSwitch infected fibroblasts and B6G-2 cells produced the Switch protein, 
but this is not seen in non-infected cells. 
 
 
Figure 37 AdSwitch made the Switch protein in mouse tail fibroblasts. 
 
To determine if AdSwitch was a functional protein, we also infected wild-type C3B6F1 
tail fibroblasts using AdSwitch and Ad5xGal4-luc at a MOI of 500, respectively, and determined 
if luciferase activity could be induced by the ligand mifepristone. As shown in Figure 38, 
mifepristone induced luciferase activity at least five times greater than the control without 
mifepristone induction. 
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After we confirmed that AdSwitch made the Switch protein in wild-type C3B6F1 mouse 
tail fibroblasts and this protein is functional to induce luciferase activity, we determined which 
line of cells from our TgGeneA-iNOS founders were inducible for iNOS expression. 
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Figure 38 Induction of luciferase activity with 10-7M mifepristone in wild-type C3B6F1 tail fibroblasts after 
cells were co-infected by AdSwitch and Ad5xGal5luc with a MOI of 500. 
3.2.4.4 Identification of iNOS inducible transgenic mice TgGeneA-iNOS using AdSwitch 
As mentioned before, we had 9 lines of cells from TgGeneA-iNOS founders for testing:  
36, 43, 56, 63, 64, 88, 100, 110 and 115. According to the cell number, these cells were seeded in 
6-well plates at a density of 1×105 cells/well or 2×105 cells/well. Each line of cells was seeded in 
3 wells of a 6-well plate. One well of cells was infected by AdSwitch, but not induced by 
mifepristone as a negative control, the other two wells of cells were infected by AdSwitch and 
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induced by mifepristone to determine iNOS induction. Theoretically, we should have more wells 
without AdSwitch infection as negative control. However, we were limited by cell number and 
this is the best experimental design under these circumstances. The infection and induction 
conditions are shown in Figure 39.  
 
Figure 39 Experimental design for induction of iNOS. 
 
As shown in Figure 39, cells were first infected by AdSwitch for 18 hrs, then allowed to 
recover for 24 hrs in fresh culture media. Next, cells were induced by 10-7M mifepristone for 24 
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hrs and the culture media was taken to measure the nitrite level using Greiss assay.  
Subsequently, the cells were induced by fresh mifepristone (10-7M) again for another 24 hrs. The 
culture media was collected to measure the nitrite level and cells were harvested for western blot.  
The nitrite levels in culture media were measured using Greiss assay. Table 6 and 7 show 
the reading of absorbance at 550 nm using Greiss assay. There was no significant induction of 
nitrite in any of cell lines at either 24 or 48 hrs after mifepristone induction 
 
Table 6 Absorbance at 550 nm in cell culture media 24 hrs after mifepristone induction. 
Mouse line Wild-type 36 43 56 63 
- Mifepristone 0.005 0.000 -0.004 -0.001 0.000 
+ Mifepristone 0.010 -0.001 0.002 0.000 0.010 
+ Mifepristone 0.015 -0.001 -0.004 0.000 0.000 
Mouse line 64 88 100 110 115 
-Mifepristone -0.006 -0.004 -0.002 0.001 -0.002 
+ Mifepristone 0.002 -0.005 0.002 0.001 -0.002 
+ Mifepristone -0.004 -0.004 N/A 0.002 -0.002 
Nitrite Standards 0 μM 1 μM 2 μM 4 μM 8 μM 
Absorbance (550 nm) 0.000 0.006 0.010 0.014 0.052 
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Table 7 Absorbance at 550 nm in cell culture media 48 hrs after mifepristone induction. 
Mouse line Wild-type 36 43 56 63 
-Mifepristone 0.005 0.001 0.004 0.002 0.000 
+ Mifepristone 0.010 0.006 0.009 0.007 0.008 
+ Mifepristone 0.015 0.007 0.013 0.008 0.000 
Mouse line 64 88 100 110 115 
-Mifepristone 0.003 -0.001 0.000 0.001 0.004 
+ Mifepristone 0.007 0.001 0.002 0.003 0.005 
+ Mifepristone 0.011 0.000 N/A 0.002 0.010 
Nitrite Standards 0 μM 2 μM 4 μM 8 μM 16 μM 
Absorbance (550 nm) 0.000 0.008 0.014 0.052 0.111 
 
In Table 6 and 7, the absorbance at 550 nm is shown but not the nitrite level. To get the 
nitrite concentration, we needed to make a standard curve according the standard nitrite 
concentration and absorbance at 550 nm. These absorbance values are at the basal level and it 
would not be accurate to convert to nitrite concentration using the standard curve because they 
are at the bottom of the standard curve. 
Next, we performed western blot analysis to detect iNOS protein expression. To 
distinguish exogenous human iNOS expression from endogenous mouse iNOS expression, a 
rabbit anti-human iNOS antibody (Biodesign international, Saco, Maine) was used for western 
blot. We have proven that this antibody specifically binds to human iNOS, but not mouse iNOS. 
As shown in Figure 40, in line 88 and 110, human iNOS was induced when given 
mifepristone, but was not expressed in non-induced cells; in line 43, 56 and 63, human iNOS 
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was expressed constitutively, with or without mifepristone induction; in line 36, 64, 100 and 115, 
human iNOS was neither expressed, nor inducible by mifepristone; in wild-type C3B6F1 tail 
fibroblasts (negative control), human iNOS was not expressed nor inducible by mifepristone. 
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Figure 40 Induction of human iNOS by mifepristone in tail fibroblasts from 9 TgGeneA-iNOS founder lines. 
Wild-type C3B6F1 mice tail fibroblast were used as a negative control. 
3.2.5 Conclusion 
We indentified a good inducible system (GeneSwitch), in which the transgene lacZ or iNOS 
exhibited strict basal expression and inducibility dependent on the concentration of the ligand 
mifepritien when tested in vitro. We modified this system to develop our vascular-specific iNOS 
inducible mice. We have successfully generated two iNOS inducible mice lines: TgGeneA-iNOS 
88 and TgGeneA-iNOS 110, in which human iNOS is not expressed at the basal condition but 
inducible when given mifepristone. These two lines are now undergoing rederivation for future 
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characterization. The other three lines TgGeneA-iNOS, 43, 56 and 63 constitutively express 
iNOS. Another four lines TgGeneA-iNOS 36, 64, 100 and 115 neither express iNOS nor 
inducible. The last three lines TgGeneA-iNOS 24, 109 and 111 could not be tested due to poor 
cell growth.  
We also successfully established a methodology by which to identify the iNOS inducible 
transgenice mice, which has not been previously reported in the literature. 
3.2.6 Discussion 
Because adenoviral vector transduction resulted in great variability in our heterotopic heart 
transplantation model, we abondoned the adenoviral vector transduction strategy. Nonetheless, 
we have successfully characterized three endothelial-specific adenoviral vectors and these 
vectors showed promise for endothelial-specific targeting in vitro. As an alternative approach, 
we made considerable progress in the development of vascular-specific iNOS inducible 
transgenic mice. We modified the GeneSwitch system to develop vascular-specific iNOS 
inducible mice. To generate vascular-specific iNOS inducible transgenic mice, two transgenic 
mice lines are required. One is TgSMMHCS-Switch or TgICAM2-Switch, in which the Switch 
protein will be regulated by the vascular-specific promoter SMMHCS or ICAM2 and will be 
constitutively expressed in smooth muscle or endothelial cells. Another is the iNOS basal 
expression transgenic mice line TgGeneA-iNOS, in which human iNOS gene is not expressed in 
normal conditions, but inducible when given the Switch protein and the inducer mifepristone. 
The DNA plasmids used to generate the three transgenic mice lines have been constructed as 
shown in Figure 11 as described in 2.16. By collaborating with Revivicor Inc., we sussessfully 
generated two iNOS basal transgenic mice lines: TgGeneA-iNOS 88 and TgGeneA-iNOS 110. 
 109 
The next step is to make transgenic mice TgICAM2-Switch and TgSMMHCS-Switch and cross 
them with TgGeneA-iNOS, respectively. Finally, we will get vascular-specific iNOS inducible 
transgenic mice TgICAM2-Switch-iNOS and TgSMMHCS-Switch-iNOS. 
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4.0  EFFICACY OF ENDOTHELIAL-SPECIFIC ENOS OVEREXPRESSION ON 
INHIBITION OF CARDIAC ALLOGRAFT ARTERIOSCLEROSIS 
In Chapter 3, we developed two gene delivery systems: adenoviral vector and vascular-specific 
iNOS inducible transgenic mice. The adenoviral vectors did not lead to consistent transduction 
results when they were used to transduce donor heart ex vivo. The iNOS inducible transgenic 
mice are still under development and it will take a while before they are ready to be used to test 
our hypothesis. To test our hypothesis that specific expression of NOS (eNOS or iNOS) in 
smooth muscle or endothelial cells will inhibit cardiac allograft arteriosclerosis, we imported 
eNOS transgenic mice from Dr. Rini De Crom (Netherland). In this transgenic mice line, the 
human eNOS promoter regulates the human eNOS endothelial-specific expression. Crossing this 
transgenic mice line with apo E knockout mice has been shown to result in regression of 
atherosclerotic lesions (159). In our project, we used this transgenic mice line as donor and tested 
if endothelial-specific overexpression of eNOS will inhibit cardiac allograft arteriosclerosis. 
4.1 DEVELOPING A CHRONIC REJECTION MODEL USING C57BL/6 MICE AS 
DONOR 
In our preliminary data, we employed a rat chronic rejection model in which PVG and ACI rats 
were used as donor and recipient, respectively. Now we shifted to use the eNOS transgenic mice 
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as donor. We needed to develop an appropriate chronic rejection model in which the wild-type 
C57BL/6 mice should be used as donor since the eNOS transgenic mice are generated from the 
C57BL/6 mice strain. We started a collaboration with Dr. Noriko Murase and Dr. Atsunori 
Nakao for the development of chronic rejection model. 
4.1.1 Combination of C57BL/6 (H-2b) and C3H/HeOuJ (H-2k) resulted in severe 
inflammation 
We first employed an MHC class I mismatched model in which male C57BL/6 (H-2b) and 
C3H/HeOuJ (H-2k) mice were used as donor and recipient, respectively. Three forms of FK506, 
oral, intramuscular (IM) and intravenous (IV), were administrated to the recipients individually 
or in combination. Five methods of immunosuppression were compared, including oral, IM, IV, 
IM + oral, and IM + IV. The dose and timing for each immunosuppression are listed in Table 8. 
 
Table 8 Five modes of FK506 Administration to recipients. 
FK506 form IM IV Oral IM + oral IM + IV 
Dose (mg/kg/day) 2.0 1.0 1.0 IM: 2.0  
Oral: 1.0 
IM: 2.0 
IV: 1.0 
timing (days) 14 14 14 IM: the first 14 days 
Oral: the first 7 days 
IM: the first 14 days 
IV: the first 7 days 
Graft survival (days) >30 19, 21 >30 >30 >30 
 
When the IV form of FK506 was given to recipients, the grafts survived less than 30 
days. Therefore, this immunosuppressive protocol was excluded. For the other four approaches 
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of immunosuppression, we compared the inflammation that developed in the donor grafts. The 
grafts were palpated daily and harvested when they stopped beating. The grafts without FK506 
treatment were used as positive controls; the isografts (both donor and recipients were C57BL/6 
mice) and native heart served as negative controls. The method that was used to determine the 
inflammation grade is described in 2.17. Briefly, each graft was cut into 2 to 4 sections from 
apex to base, numbered as 1, 2, 3 and 4, respectively. The heart tissue was embedded into 
paraffin and H&E staining slides were made for each section. Inflammation was graded 
according to the 1990 IHLTS grading system.  
As shown in Table 9 and Figure 41, with the four methods of immunosuppression (IM, 
oral, IM + oral, IM + IV of FK506), the donor grafts survived from 34 to 93 days except for a 
few grafts that failed before 12 days due to technical failure. In the surviving wild-type donor 
grafts, all developed active inflammation with grades of 3A, 3B or 4. Extensive infiltrates 
accumulated in myocardium and vasculature. The coronary vessels developed endothelialitis and 
the middle layer exhibited vasculitis. However, mild inflammation appeared in the wild-type 
grafts HB14 and HB31, which failed at 6 and 12 days after transplantation due to technical 
failure. Compared to HB28 and HB29 (without FK506 treatment) that generated myocardial 
infarction and necrosis, modest inflammation developed in the grafts HB14 and HB31 (with 
FK506) indicating that FK506 actually suppressed the immune reaction well during the first two 
weeks after transplantation. Active inflammation is normally observed during the acute rejection 
stage after heart transplantation when there is no immunosuppression or immunosuppression is 
weak, but not in the chronic stage. In our heart transplantation model, FK506 suppressed acute 
rejection. However, severe inflammation persisted in the graft at 60 or even 93 days after 
transplantation. Therefore, the long-term inflammation generated in the allografts very likely 
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came from the MHC haplotype mismatch between donor and recipient. The transgenic donors 
HB32 and HB33 also demonstrated similar extensive inflammation, which was not significantly 
different from the wild-type donors. One exception is that the transgenic donor HB35 exhibited 
mild inflammation (inflammation grade is 1A/1B). However, since more than 50% of the graft 
tissue was necrotic, this graft should not be taken as representative. 
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Table 9 Inflammation grade in allografts with four modes of FK506 administration. 
Donor # 
(genotype) 
Days post 
transplant-
tation 
FK506 
administration
Inflammation grade 
HB11 (WT) 70 IM 3A 
HB13 
(WT)  
section 1 93 IM 3B 
section 2 93 IM 3B 
HB24 
(WT) 
section 1 34 Oral 4 
section 2 34 Oral 4 
HB23 
(WT) 
section 1 63 Oral 4 
section 2 63 Oral 4, no myocytes 
HB25 
(WT) 
section 1 90 Oral 4 
section 2 90 Oral 4 
HB 16 (WT) 34 IM--Oral 3B, no significant change in the vessel 
HB 17 (WT) 35 IM--Oral 3A/3B, vasculitis and endothelialitis 
HB 15 (WT) 36 IM--IV 3B 
HB 18 (WT) 68 IM--IV 3A 
HB 29 (WT) 11 No treatment Myocardial infarction 
HB 28 (WT) 13 No treatment Difficult to judge, infarction, 70% necrosis 
HB 32 
(Tg) 
section 1 45 IM--Oral 3A, focal transmusal + vascularitis 
section 2 45 IM--Oral 3B, focal transmusal + vascularitis 
section 3 45 IM--Oral 3A, endothelialitis 
HB 33 section 1 34 IM--Oral 4, multifocal and severe vasculitis 
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(Tg) section 2 34 IM--Oral 4, multifocal and severe vasculitis 
HB 34 
(WT) 
section 1 45 IM--Oral 3B, multifocal vasculitis 
section 2 45 IM--Oral 3A, multifocal vasculitis 
section 3 45 IM--Oral 3A, multifocal vasculitis 
HB 35 
(Tg) 
section 1 38 IM--Oral 1A/1B, myocardial infarction, 50% is 
necrotic, no vasculitis, no endothelialitis 
section 2 38 IM--Oral 1A/1B, myocardial infarction, 70% is 
necrotic, no vasculitis, no endothelialitis 
HB 36 
(WT) 
section 1 44 IM--Oral 1B, endothelialitis 
section 2 44 IM--Oral 3A, endothelialitis + mild vasculitis+ 
multifocal transmusal 
section 3 44 IM--Oral 3A, endothelialitis + mild vasculitis+ 
multifocal transmusal 
HB 14 (WT) 6 IM 1A 
HB 31 
(WT) 
section 1 12 IM--Oral 1A/1B, no vasculitis 
section 2 12 IM--Oral 1A/1B, no vasculitis 
HB 37 
(Tg) 
section 1 2 IM--Oral 1A 
section 2 2 IM--Oral 1A 
section 3 2 IM--Oral 1A 
 
Figure 41 demonstrates the inflammation grade for each allograft according to Table 9. 
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Figure 41 Inflammation grade in the donor graft with different modes of FK506 administration. 
 
H&E staining further confirmed that severe inflammation generated in the donor grafts, 
as shown in Figure 42. 
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Figure 42 H&E staining of donor grafts with different modes of FK506 administration. 
The grafts were palpated daily and harvested when they stopped beating. A: IM, 70 days after transplantation 
(HB11), inflammation grade 3A; B: IM, 93 days after transplantation (HB13), inflammation grade 3B; C: Oral, 34 
days after transplantation (HB23), inflammation grade 4; D: Oral, 63 days after transplantation (HB24), 
inflammation grade 4; E: IM+IV, 36 days after transplantation (HB15), inflammation grade 3B; F: IM+IV, 68 days 
after transplantation (HB18), inflammation grade 3A; G: IM+Oral, 34 days after transplantation (HB16), 
inflammation grade 3B; H: IM+Oral, 35 days after transplantation (HB17), inflammation grade 3A/3B; I: No FK506 
treatment, 13 days after transplantation (HB28); J: No FK506 treatment, 11 days after transplantation (HB29); K: 
C57BL/6 isografts, 60 days after transplantation; L: Native heart. I and J (without FK506 treatment) were used as 
positive controls; K (isografts) and L (native heart) were used as negative controls.  
K L
I J
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4.1.2 Combination of C57BL/6 (H-2b) and C3H/HeOuJ (H-2k) did not develop significant 
cardiac allograft arteriosclerosis 
To characterize the development of cardiac allograft arteriosclerosis, donor hearts from wild-type 
C57BL/6 mice and eNOS transgenic mice were transplanted into wild-type C3H/HeOuJ mice. 
Three donors were used for each group. The transgenic donors were named HB32, HB33 and 
HB35; the wild-type donors were named HB31, HB 34 and HB36. The combination of IM and 
oral forms of FK506 is thought to be more effective because the two routes have different 
kenetics. The oral form results in hight levels for a short period while the IM form results in 
sustained but lower levels. Thus, adequate FK506 levels are assured when both routes are used 
simultaneously. Therefore, our immunosuppression protocol evolved to the administration of the 
IM form of FK506 to recipients for the first 14 days after transplantation at a dose of 2.0 
mg/kg/day, combined with the oral form of FK506 for the first 7 days at a dose of 1.0 
mg/kg/day. Donor grafts were harvested at 45 days after transplantation. At this time point, only 
three donor grafts survived, including one transgenic (HB32) and two wild-type grafts (HB34 
and HB36). For the other three grafts, HB31 was lost at 12 days after transplantation because of 
technical failure. HB33 and HB35 were harvested at 34 and 38 days after transplantation, 
respectively, when the grafts stopped beating. 
As described in 2.18, to evaluate the degree of cardiac allograft arteriosclerosis, HB32, 
34 and 36 were cut into 2 to 4 sections, respectively, and each section was embedded into 
paraffin. For each section, cross sections were cut at two levels, which were 40 μm apart. Tissue 
sections were stained using verhoeff's Van Geison (vVG) stain and vessel occlusion was 
evaluated. As shown in Figure 43, “bubbling” occlusion developed in coronary vessels with 
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foam cells and leukocytes infiltrated and accumulated in the lumen. Both transgenic and wild-
type donor grafts developed “bubbling” occlusion.  
     
     
Figure 43 “Bubbling” occlusion developed in coronary vessels of both transgenic and wild-type grafts. 
The grafts were harvested at 45 days after transplantation. A and B: HB32, eNOS transgenic donor; C: HB34; wild-
type donor; D: HB36, wild-type donor. 
 
As shown in Figure 44, H&E staining demonstrated that severe inflammation developed 
in both transgenic and wild-type donor grafts. The inflammation grades in these grafts were 3 or 
4 except for HB35, which exhibited extensive necrosis. 
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Figure 44 Severe inflammation developed in both transgenic and wild-type donor grafts. 
A: HB32, eNOS transgenic donor, 45 days after transplantation, inflammation grade 3A/3B; B: HB33, eNOS 
transgenic donor, 34 days after transplantation, inflammation grade 4; C: HB35, eNOS transgenic donor, 38 days 
after transplantation, inflammation grade 1A/1B, necrotic; D: HB35, eNOS transgenic donor, 38 days after 
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transplantation, inflammation grade 1A/1B, necrotic; E: HB34, wild-type donor, 45 days after transplantation, 
inflammation grade 3A/3B; E: HB36, wild-type donor, 45 days after transplantation, inflammation grade 3A. 
 
This chronic rejection model did not lead to the development of cardiac allograft 
arteriosclerosis. The presence of “bubbling occlusion” suggested that intimal hyperplasia in the 
coronary vessels may have occured at the early stage of development. However, mature cardiac 
allograft arteriosclerosis should exhibit fibrotic, collagen-rich and smooth muscle cell-dominated 
intimal thickening with monocyte and lymphocyte infiltration. Figure 45 left (182) represents a 
cross section of left anterior descending coronary artery from a 52-year old woman with severe 
cardiac allograft arteriosclerosis. The right picture in Figure 45 represents another example of 
mature cardiac allograft arteriosclerosis from a patient (239). Moreover, in this chronic rejection 
model, severe inflammation (grade 3 or 4) developed in donor grafts with endothelialitis and 
vascularitis (as shown in Table 9, Figure 42 and Figure 44) even with immunosuppression with 
FK506. During the natural development of cardiac allograft arteriosclerosis in human heart, only 
mild-inflammation (grade 1A or 1B) is observed (Figure 46, 182). Therefore, this chronic 
rejection model did not mimic the natural development of this disease well. Furthermore, in this 
chronic rejection model, the graft survival rate was low. We performed eight transplantations in 
total and five grafts (HB31, HB33, HB35, HB39 and HB40) did not survive with the required 45 
days. Due to the reasons given above, we chose another chronic rejection model. 
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Figure 45 Cardiac allograft arteriosclerosis developed in human biopsy. 
Left: from literatue 182; Right: from literature 239. 
 
 
Figure 46 Mild inflammation developed in human biopsy with cardiac allograft arteriosclerosis (189). 
4.1.3 Combination of male and female C57BL/6 mice resulted in mild inflammation and 
modest cardiac allograft arteriosclerosis 
The first chronic rejection model did not lead to cardiac allograft arteriosclerosis. Next, we chose 
another MHC class II mismatched model in which male and female C57BL/6 mice were used as 
donor and recipient, respectively, and no immunosuppressive was given. This model was 
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developed by Uehara et al., who showed that 56 days after transplantation, intimal hyperplasia 
developed in the donor cardiac grafts (174). 
To determine if cardiac allograft arteriosclerosis developed in the wild-type donor graft 
and the effect of eNOS overexpression on cardiac allograft arteriosclerosis, donor hearts from 
male wild-type C57BL/6 mice or eNOS transgenic mice were transplanted into female wild-type 
C57BL/6 mice. The donor grafts were harvested at 60 days after transplantation. The transgenic 
donors were named HB45, HB53 and HB54, and the wild-type donors were named HB44, 
HB62, HB63, HB64, HB65 and HB66. As represented in Figure 47, mild inflammation 
developed in both wild-type and transgenic donor grafts and the inflammation grade for these 
grafts is 1A/1B. There was no significant difference between wild-type and transgnenic donors. 
Compared to the first chronic rejection model that developed severe inflammation (grade is 3 or 
4), the inflammation that developed in the second chronic rejection model better mimicked the 
human condition.  
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Figure 47 Mild-inflammation developed in both transgenic and wild-type donor. 
All of the grafts were harvested at 60 days after transplantation and the grafts were functional well. A, B: HB45, 
eNOS transgenic donor; C: HB53, eNOS transgenic donor; D: HB54, eNOS transgenic donor; E: HB62, wild-type 
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donor; F: HB63, wild-type donor; G: HB64, wild-type donor; H: HB66, wild-type donor. The inflammation grades 
in the seven grafts are 1A/1B. 
Moreover, in the second chronic rejection model, mature intimal thickening was observed 
in the coronary vessels of wild-type donor grafts, especially in large- and middle-sized vessels 
(Figure 48). In these vessels, the neointima layer exhibited fibrotic and smooth muscle cell-rich 
occlusions with some infiltrates. At the same time, some of the vessels developed bubbling 
occlusion and some vessels are intact. Furthermore, except for the grafts that failed due to 
technical reasons, the graft survival rate (percentage of the grafts that beated well until harvest at 
60 days after transplantation) was high (73.8%). Therefore, this chronic rejection model gave 
better results. 
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Figure 48 Mature cardiac allograft arteriosclerosis developed in both transgenic and wild-type donor grafts. 
A and B: HB53, transgenic donor; C and D: HB54, transgenic donor; E: HB44, wild-type donor; F: HB62, wild-type 
donor; G: HB63; wild-type donor; H: HB64; wild-type donor. 
 
To determine the effect of endothelial-specific eNOS overexpression on cardiac allograft 
arteriosclerosis, we compared vessel occlusion between wild-type and transgenic grafts. The 
genotype of both donor and recipient mice was confirmed by PCR using the human specific 
eNOS primer as suggested by Dr. Crom (159). Figure 49 shows that HB45, HB53 and HB54 
donors are transgenic by PCR. We also confirmed that the human eNOS protein was 
overexpressed in transgenic donors by immunohistochemistry, as represented in Figure 50.  
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Figure 49 PCR results show that HB45, HB53 and HB54 donors were eNOS transgenic. 
From left to right, 1: eNOS transgenic control; 2: wild-type control; 3: HB45 donor; 4: HB53 donor; 5: HB54 donor. 
 
   
Figure 50 Immunohistochemistry confirmed that eNOS protein was overexpressed in transgenic donor mouse 
aorta. 
A: HB45 donor aorta, eNOS trasnsgenic; B: HB44 donor aorta, wild-type C57BL/6 mouse. 
 
The functional grafts were harvested at 60 days after transplantation. The method to 
evaluate vessel occlusion was described in 2.18. Figure 51 shows percentage of vessel occlusion 
of three transgenic donor grafts, including HB45, HB53 and HB54, and six wild-type donor 
grafts, including HB44, HB62, HB63, HB64, HB65 and HB66. Figure 52 shows the mean and 
standard deviation of the mean of the six wild-type and three transgenic grafts. Vessel occlusion 
 eNOS     Wild-type     HB45       HB53        HB54 
transgenic 
eNOS 
Flt3 Control 
A, transgneic  B, wild-type 
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in the transgenic grafts was not significantly different from that of wild-type grafts. We also 
graded the vessel occlusion according to the method described by Dr. Anthony J. Demetris (175) 
on 2.18. As shown in Figure 53, the grade of vessel occlusion correlated very well with the 
percentage of vessel occlusion. The grade of vessel occlusion was not significantly different 
between transgenic and wild-type grafts. 
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Figure 51 Vessel occlusion developed in transgenic and wild-type donor grafts. 
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Figure 52 Vessel occlusion in wild-type and eNOS transgenic donor grafts did not show significant difference. 
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Figure 53 Grade of vessel occlusion in transgenic and wild-type donor grafts. 
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4.1.4 Conclusion 
We successfully developed a mouse chronic rejection model, in which male and female C57BL/6 
mice were used as donor and recipient, respectively. In this chronic rejection model, modest 
cardiac allograft arteriosclerosis developed at 60 days after transplantation and mild 
inflammation was seen in the graft tissues. This model mimics the natural development of 
cardiac allograft arteriosclerosis. Another chronic rejection model we tried involved the use of 
male C57BL/6 and male C3H/HeOuJ mice as donor and recipient, respectively. Immature 
cardiac allograft arteriosclerosis and severe inflammation developed in the recipients. The severe 
inflammation persisted up to 60 and 93 days after transplantation even with FK506. This model 
did not mimic the natural disease well. 
Endothelial-specific overexpression of human eNOS driven by the human eNOS 
promoter in eNOS transgenic mice did not exhibit significant suppression of cardiac allograft 
arteriosclerosis. 
4.1.5 Discussion 
Endothelial overexpression of eNOS in eNOS transgenic/apo E knockout mice has been shown 
to suppress atherosclerotic lesion by van Haperen et al. (159). Paradoxically, in another eNOS 
transgenic mice line in which the murine preproendothelin-1 promoter regulated the bovine 
eNOS overexpression, Ozaki et al. showed that eNOS overexpression accelerated the 
atherosclerotic lesion in eNOS/apo E knockout transgenic mice (176). This controversy led to the 
question: what happens when eNOS is overexpressed in transgenic mice? NO levels in the aorta 
of eNOS transgenic mice have been shown to be much higher than that of wild-type mice (177).  
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Meanwhile, superoxide levels in eNOS transgenic mice was significantly upregulated and the 
amount of (6R)-5,6,7,8-tetrahydrobiopterin (BH4) in the aorta, an essential cofactor of eNOS, 
significantly decreased, compared to that of wild-type mice (178).  The increased superoxide 
level is likely due to “eNOS uncoupling”, when the availability of BH4 becomes rate-limited. 
The concept of “eNOS uncoupling” has been studied extensively, which is characterized by a 
stoichiometric discordance between eNOS protein levels and NO production. 
BH4 plays an important role in the catalytic process of L-arginine oxidation and NO 
synthesis by eNOS (180). There is one BH4 binding site in the oxygenase domain of each 
monomer, so 2 molecules of BH4 are incorporated into each functional eNOS dimmer (Figure 
54, 181). In vitro experiments with electron paramagnetic resonance spectroscopy demonstrated 
that BH4 stabilizes the dimeric form of the enzyme and donates electrons to the ferrous-dioxygen 
complex in the oxygenase domain, as the initiating step of L-arginine oxidation. BH4 forms the 
protonated trihydrobiopterin cation radical BH3.H+, which is subsequently reduced by electron 
transfer from eNOS flavins (Figure 55, 177). When BH4 is limiting, electron transfer from eNOS 
flavins becomes uncoupled from L-arginine oxidation, the ferrous-dioxygen complex dissociates, 
and superoxide is produced from the oxygenase domain. 
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Figure 54 Subunit composition of eNOS. Left panel shows the enzyme in the resting state. 
Right panel shows the enzyme in an active form where electrons flow from reductase to oxygenase domain enabling 
the conversion of L-arginine to †NO and L-citrulline.  
 
To overcome this, Channon et al. developed an eNOS/GTPCH double transgenic mice in 
which the murine preproendothelin-1 promoter regulates the bovine eNOS overexpression and 
the murine Tie2LE promoter drives the expression of GTP cyclohydrolyse (GTPCH) (179). The 
schematic structure of this double transgenic line is shown in Figure 56. GTPCH is a rate-
limiting enzyme for the generation of BH4. Overexpression of GTPCH led to increased level of 
BH4 and decreased level of superoxide in eNOS/GTPCH double transgenic mice compared to the 
eNOS single transgenic mice (177). To evaluate the role of BH4 on eNOS transgenic mice, the 
eNOS/GTPCH double transgenic mice were crossed with apo E knockout mice. Overexpression 
of eNOS in eNOS/GTPCH double transgenic/apo E knockout mice reduced the atherosclerotic 
lesion compared to that of eNOS transgenic/apo E knockout mice (179). This study supports the 
notion that BH4 plays an important role on NO production in eNOS transgenic mice. If BH4 is 
deficient, there is no guarantee that the increased eNOS protein will be functional.  
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Figure 55 Schematic model for oxidation of L-arginine or NHA by NOS. 
 
Figure 56 Schematic structure of eNOS/GTPCH double transgenic mice. 
4.2 FUTURE DIRECTIONS 
We have imported the eNOS/GTPCH double transgenic mice from Dr. Keith M Channon 
(Figure 56). We plan to use this transgenic mice as donor and test our hypothesis that 
overexpression of eNOS in endothelial cells plays an inhibitory role on the development of 
cardiac allograft arteriosclerosis. 
Murine Tie2 promoter Human GTPCHMurine Preproendothelin 1 
promoter 
Bovine eNOS 
 
 135 
Meanwile, we are still developing vascular-specific iNOS inducible transgenic mice. We 
have obtained two lines of iNOS basal expression transgenic mice, named as TgGeneA-iNOS 88 
and TgGeneA-iNOS 110. We will make two more transgenic mice lines TgSMMHC-Switch and 
TgICAM2-Switch. TgGeneA-iNOS 88 and 110 will be crossed with the vascular-specific Switch 
transgenic mice with the goal of producing vascular inducible iNOS transgenic mice. If these 
two lines of mice are successfully generated, we will be able to test if induction of iNOS in 
endothelial cells or smooth muscle cells will play the dominant role on the development of 
cardiac allograft arteriosclerosis. 
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